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Summary 
        Mitosis is the process during which a eukaryotic cell segregates the chromosomes into 
two identical daughter cells. The chromosomes are physically separated to the opposite poles 
of the cell by the mitotic spindle, which is a highly dynamic microtubule (MT)-based 
macromolecular machine. Spindle assembly begins early in mitosis and is completed when 
the bipolar attachment of microtubules to kinetochore (KT) pairs is achieved. Many mitotic 
spindle associated proteins are regulated by phosphorylation and dephosphorylation. A 
comprehensive phosphorylation site mapping of mitotic spindle proteins would help us to 
gain a better understanding of its functions and regulation in mitotic progression. 
        Mass spectrometry (MS) has become the most powerful and robust tool for protein 
identification and the study of their post-translational modifications. The development of MS 
hardware and data processing software made large scale quantitative proteomics and 
phosphoproteomics studies feasible. 
        In the project of quantitative identification of Polo-like kinase 1 (Plk1) specific 
phosphorylation sites on human mitotic spindle proteins, we present the first quantitative 
study of the Polo-like kinase 1 (Plk1) dependent phosphoproteome of the human mitotic 
spindle. Mammalian Plk1 controls centrosome maturation, spindle assembly and microtubule 
attachment to kinetochores. However, despite the essential and diverse functions of Plk1, only 
a limited number of substrates have been identified. In our study, we combine SILAC with 
Plk1 depletion or inactivation, followed by spindle isolation and mass spectrometry to 
compare the phosphoproteomes of mitotic spindles isolated from cells lacking Plk1 activity to 
spindles from cells with fully active kinase. We report the down-regulation of more than 700 
phosphorylation sites upon Plk1 inactivation, including 360 sites on known spindle proteins, 
of which more than 100 were validated as direct Plk1 targets using in vitro phosphorylation of 
synthetic peptide arrays. This approach identifies many novel Plk1 substrates and suggests a 
broader phosphorylation consensus motif for this kinase than previously recognized. 
Furthermore, we analyze in a quantitative manner the consequences of Plk1 inactivation on 
the localization of its substrates to the spindle. We report the mis-localization of certain 
centrosomal and kinetochore proteins upon Plk1 inhibition and further analyze the 
kinetochore protein CENP-F as an example. Finally, we identify several Aurora A-dependent 
phosphorylation events that depend on Plk1, thus highlighting the role of Plk1 in the 
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regulation of Aurora A activity. Collectively, our data provides a rich source of information 
on Plk1-dependent phosphorylation, Plk1 docking to substrates, the influence of 
phosphorylation on protein localization, and the functional interaction between Plk1 and 
Aurora A on the early mitotic spindle.  
        In the project of phosphoproteome analysis of human mitotic spindle proteins by using 
the low-specificity protease elastase, we evaluated the use of elastase in a phosphoproteome 
study of human mitotic spindle associated proteins. Despite the usefulness and obvious 
advantages of trypsin in bottom-up proteomics experiments, it still has certain limitations in 
sequence coverage and cleavage efficiency. As an alternative to specific enzymes, low-
specificity proteases have attracted our attention. Elastase became the enzyme of choice to 
supplement tryptic digestions, mainly because it generates medium sized peptides in the mass 
range between 500 Da and 1500 Da which are optimal for detection with current LC-MS 
hardware. We took advantage of the high mass accuracy of Orbitrap mass spectrometers and 
optimized the database search specificity by analyzing both elastase cleavage preferences and 
employing a dedicated two-step database search strategy. Through this approach, we have 
approximately doubled the number of detectable phosphorylation sites from elastase digested 
samples. Remarkably, phosphorylation sites detected by trypsin and elastase were highly 
complementary with an overlap of less than 10%. In total, we identified 1068 phosphorylation 
sites using trypsin and 467 phosphorylation sites using elastase. Approximately 30% of the 
phosphorylation sites were exclusively identified after digestion by elastase, demonstrating 
the value of this enzyme for phosphoproteome studies. 
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1 Introduction 
1.1 Cell cycle 
      The cell cycle is an ordered series of events that take place in a cell and leads to its 
division and replication. Newly formed daughter cells can themselves grow and divide. In 
bacteria and yeast, each round of cell division is sufficient to produce a complete new 
organism. In higher eukaryotes, multiple and complex rounds of cell divisions are required to 
produce functional organism and to replace dead cells. The most fundamental characteristic of 
cell cycle through all living organism is to pass on exact genetic information to newly formed 
daughter cells. To accomplish this, each cell first duplicates its genetic material and then 
equally segregates it between two daughter cells to ensure each cell retains the exact same 
content of genetic information. In eukaryotes, this process is divided into four sequential 
phases: G1 (Gap phase1), S (Synthesis phase), G2 (Gap phase2) and M (Mitosis and 
cytokinesis). DNA synthesis and replication occur in S phase. In M phase, cell growth and 
protein production are greatly reduced, and duplicated chromosomes segregate equally to the 
daughter cells. Between S and M phases, there are two gap phases called G1 and G2. During 
G1 (after M phase and before S phase), cells grow in size, produce RNA and synthesize 
proteins. In G2 (after S phase and before M phase), cells continue to grow and prepare for 
entry into mitosis. 
1.2 Mitosis 
Mitosis is relatively brief but a key event during the cell cycle. In M phase, equal 
segregation of genetic and cytoplasmic material takes place. Mitosis has five stages: prophase, 
prometaphase, metaphase, anaphase and telophase (figure 1). In prophase, the interphase 
chromatin condenses into chromosomes, which each comprises two chromatids held together 
by protein complex cohesion. The centrosomes, which have been duplicated during S phase, 
start moving to opposite poles and increase the nucleation of highly dynamic microtubules 
(MTs) to build mitotic spindles 1, 2. During prometaphase, the nuclear envelope breaks down. 
The microtubules emanating from opposite spindle poles are captured by kinetochores which 
are situated on the centromeres of both sister chromatids. Attached chromosomes are then 
moved to the equator of the cell in a process called chromosome congression. In metaphase, 
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all attached chromosomes align on an equatorial plate known as the metaphase plate in the 
middle of the cell. Once all chromosomes are properly aligned, the spindle assembly 
checkpoint, which is a surveillance mechanism that is active in prometaphase to prevent 
inaccurate separation of the sister chromatids, is satisfied. This leads to anaphase promoting 
complex mediated ubiquitin-dependent degradation of the separase inhibitor securin, resulting 
in the removal of sister chromatid cohesion and anaphase onset. In anaphase A, the sister 
chromatids separate and are pulled to the opposite poles by shortening of kinetochore 
microtubules. In anaphase B, the centrosomes move towards the cell cortex accelerating 
chromosome separation. Mitosis ends with telophase, in which the nuclear envelope reforms, 
the chromosomes arrive at the poles of spindles and start decondensing. 
 
 
Figure 1. Schematic representation of different stages of mitosis and cytokinesis. The colours shown 
here are brown for DNA,  light green for centrosomes and dark green for MTs.  Image adapted from 
Alberts et al, Molecular Biology of the Cell, fourth edition, 2002. 
Mitosis is followed by cytokinesis. In cytokinesis, the contraction of an actomyosin-
based contractile ring (formed during late anaphase) takes place at the site of the spindle 
midzone, leading to furrow ingression. Cell division is completed by abscission and two 
daughter cells are formed, each with one nucleus and one centrosome 3. 
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1.2.1 The mitotic spindle 
Mitotic spindles pull the sister chromatids apart and move a complete set of 
chromosomes to each pole of the cell, where they are packaged into daughter nuclei. This 
ensures the faithful segregation of the genetic material during mitosis. 
 
 
 
 
 
 
 
 
 
Figure  2.  The  features  of  the metaphase mitotic  spindle. With  their minus  ends  tethered  at  the 
spindle  poles, microtubules  extend  either  to  the  kinetochores  of  paired  chromatids  (kinetochore 
fibers),  to  the  central  spindle  where  they  form  an  overlapping  antiparallel  array  (inter  polar 
microtubules), or away from the spindle towards the cell cortex (astral microtubules). Image adapted 
from Gadde S et al, Current Biology, 2004. 
The microtubule array is biopolar, with minus ends tethered at the poles and plus ends 
attached to the chromosomes (figure 2). In most vertebrate cells, the spindle poles are the 
microtubule organizing centers, they are formed by the centrosomes. The mitotic spindle is a 
highly dynamic microtubule-based structure. Microtubules continuously grow and shrink, this 
behavior is regulated by motor proteins which can travel along microtubules, and many other 
microtubule associated proteins (MAPs) which have important roles in the assembly and 
stability of the microtubule array and the movement of chromosomes on the spindle. 
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1.2.2 Phosphorylation in mitotic progression 
Mitotic progression is regulated by reversible protein phosphorylation (figure 3) and 
irreversible protein degradation. These two mechanisms are interdependent since the 
proteolytic machinery is regulated by phosphorylation and many mitotic kinases are down-
regulated by protein degradation. Cyclin-dependent kinase 1 (Cdk1), Polo-like kinase 1 (Plk1) 
and Aurora kinases are the most prominent and well characterized mitotic regulatory kinases. 
Cdk1 protein level is constant throughout the cell cycle. Its catalytic subunit has to bind to a 
regulatory subunit called cyclin (Cyclin A or B) to become enzymatically active 4, 5.  
 
 
 
 
 
 
 
 
 
 
Figure  3.  Kinases  play  important  roles  at  different mitotic  stages.  Image  adapted  from Nigg  E  A, 
Nature Reviews, Molecular Cell Biology, 2001 
Activated Cdk1 has many phosphorylation substrates in all mitotic stages, including 
proteins important for nuclear envelope breakdown, chromatin condensation, spindle 
assembly and centrosome separation. Furthermore, Cdk1/Cyclin B complexes are involved in 
the regulation of the anaphase-promoting complex/cyclosome (APC/C) which triggers the 
degradation of several mitotic regulators such as securin and Cyclin B itself 6, 7. 
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Aurora kinases are also highly active during mitosis. Aurora A activity is closely 
associated with the centrosomes and spindle assembly form prophase to telophase 8. It 
controls the timely mitotic entry by modulating nuclear envelope breakdown 9 and assists in 
centrosome maturation. Aurora B localizes to kinetochores and central spindles at different 
mitosis stages 10. The kinase activity of Aurora B is required for spindle checkpoint signaling, 
central spindle formation and cytokinesis 11. 
1.3 Polo-like kinase 1 (Plk1) 
Polo-like kinase 1 is well-characterized and has been reported to be involved in all 
phases of mitosis12-14. It is highly conserved from yeast to human 14. Plk1 N-terminal harbors 
the kinase catalytic domain whereas the C- terminal features a polo-box domain (PBD). The 
PBD is required for Plk1 substrate targeting and subcellular localization. It recognizes and 
binds to phosphorylated docking proteins, which results in a conformational change and 
liberates the kinase domain of Plk1. Activated Plk1 can then phosphorylate either the docking 
proteins or downstream targets 15. The docking proteins are phosphorylated by the so-called 
priming kinases. Cdk1/Cyclin B, Calmodulin dependent kinase II 16, MAP kinase Erk2 17 and 
Plk1 itself 18 are the most prominent priming kinases. 
The localization of Plk1 is highly dynamic throughout mitosis. It accumulates at 
centrosomes during early mitosis to regulate centrosome maturation and separation 14, 19. It 
also binds to the kinetochores to assure their correct attachments to the mitotic spindle 20. Plk1 
is further involved in the dissociation of chromosome cohesion through the removal of 
cohesin, which holds the two sister chromatids together21, 22. In addition, Plk1 has been shown 
to regulate the function of the anaphase-promoting complex/cyclosome (APC/C), which is 
essential for mitotic exit 7, 23. At metaphase-anaphase transition, Plk1 relocalizes to the spindle 
midzone and plays a key role in cytokinesis 14. 
1.4 Mass spectrometry based proteomics 
1.4.1 General workflow of MS-based proteomics 
Modern proteomic approaches include mass spectrometry, protein microarray 
technologies, large scale two-hybrid analysis, high-throughput protein production and 
crystallization 24.  
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Mass spectrometry measures the mass-to-charge ratios (m/z) of ionized molecules in the 
gasphase and can be used to determine the elemental composition provided that the mass 
accuracy of the instrument is sufficiently high. In proteomics, the measured m/z ratios and 
fragmentation patterns reflect the amino acids composition and modifications of analyzed 
peptides or proteins. In the past decade, mass spectrometry has been developed further 
successfully and become a popular technique in a wide variety of biological studies, 
especially for protein identification, the determination of protein post-translational 
modifications, and the study of protein-protein interactions. 
There are two general approaches in MS: “bottom-up” and “top-down”. In the “bottom-
up” strategy, proteins are enzymatically digested into peptides using proteases. The collection 
of peptide products is then analyzed by the mass spectrometers. In the “top-down” strategy, 
intact proteins are directly ionized and analyzed by mass spectrometry. 
 
Figure  4.  General workflow  of  bottom‐up MS‐based  proteomics  experiment.  Illustration  adapted 
from Steen H et al., Nature Reviews on Molecular Cell Biology, 2004. 
 
Due to the advantages in detection sensitivity, sample preparation, ionization and 
fragmentation efficiency, “bottom-up” is by far the most widespread and successful method in 
MS-based proteomics. A general workflow is depicted in figure 4. The proteins to be 
analyzed are isolated or purified from cells or tissues. The purification of proteins often 
includes gel electrophoresis as the last step. The proteins are then separated in the gel 
according to their molecular weight or isoelectric point. The obtained gel lane is cut into 
several slices, and then in-gel digestion of proteins is performed. Various proteases or 
chemicals are available for this step. For the most popular enzyme trypsin, most peptides 
consist of 6-20 amino acids, which is optimal for detection and identification by mass 
spectrometry. Prior to MS analysis, the peptide mixtures normally undergo single or multiple 
dimensions of on-line or off-line separation. Peptides are then ionized, their m/z values 
determined by mass spectrometry, and further structural information generated by low energy 
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excitation (MS/MS fragmentation). Finally, obtained mass spectra are searched against 
protein databases via computer algorithms, returned search results identify peptide sequences 
and post-translational modifications, thus allowing the identification of proteins and the 
characterization of their modifications 25, 26. 
In the “top-down” approach, intact proteins are directly ionized and measured in mass 
spectrometers without previous proteolytic digestion. MS/MS fragmentation is also 
performed by various activation methods. As an alternative approach, “top-down” obtains 
better sequence coverage for protein identifications, and it can in principle provide complete 
information on post-translational modifications. However, the application is usually limited to 
small proteins with molecular weight up to 30 kDa and the analytical sensitivity is low 
compared to the bottom-up strategy. Furthermore, insufficient automated hardware and 
software tools within the field make high throughput and routine laboratory use very difficult 
27, 28. 
1.4.2 MS instrumentation 
A mass spectrometer measures the mass to charge ratio in the gas phase of ionized 
analytes. A complete MS system consists of an ion source, a mass analyzer and a detector. 
Typically, the peptide or protein ions are generated in the ion source by one of two soft 
ionization methods: electrospray ionization (ESI) 29 and matrix-assisted laser 
desorption/ionization (MALDI) 30.  
In the field of proteomics, time-of-flight (TOF), ion trap, quadrupole, Fourier transform 
ion cyclotron resonance (FTICR)-MS and Orbitrap 31 analysers are the most frequently used 
instruments 25.  
1.4.2.1 Electrospray ionization (ESI) 
Dole and colleagues introduced the idea of using electrospray dispersion to produce gas 
phase ions from solutions in 1968. Fenn and coworkers applied this technique to 
biomolecules and developed the modern day ESI 29. Further improvements were made by 
Mann and coworkers in the development of nanoelectrospray ionization (nanoESI), which is 
compatible with nano-flow rates for minute amount of samples thus strongly increasing the 
detection sensitivity 32 . 
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Electrospray generates gas phase ions with high efficiency and is extremely gentle, 
enabling the study of a wide range of polar biomolecules by mass spectrometry 33. Since large 
biomolecules become usually multiply charged upon ESI, these high-mass ions can still be 
detected by instruments with a relatively low m/z detection range (frequently 50-2000 Da). 
Furthermore, since samples are applied in solution, ESI is compatible with many types of 
separation techniques such as liquid chromatography and capillary electrophoresis.  
 
 
 
 
 
 
 
 Figure 5. Schematic presentation of the electrospray ionization process. From Nielsen et al 34. 
In the classical ESI process, the sample dissolved in a polar solvent such as 
methanol/water flows through a fine capillary or a needle with a thin, sharp, conductive tip to 
which positive or negative high voltage of several kilovolts is applied. The capillary is placed 
towards the ESI source, of which the orifice is warmed up to around 150-200 degrees to aid 
desolvation. The surface of the emerging liquid gets charged under such a high voltage field 
and is being attracted toward the counter-charged electrode, whereas the surface tension acts 
in an opposite direction.  As a result of these two forces, a pointed liquid cone forms at the tip 
of the capillary if the electric field is sufficiently strong. If the strength of the electric field 
increases further, a thin, charged liquid jet emerges from the cone, which quickly subdivides 
into smaller charged droplets to minimize its surface area29. The droplets quickly shrink by 
evaporation and become unstable as the charge density on the surface increases. This leads 
the droplets to blow apart into a cloud of tiny, highly charged droplets which move towards 
the orifice (figure 5). As the droplets move, more and more solvent evaporates and eventually 
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charged solute molecules are liberated into the gas phase of which the m/z ratio can be 
determined by the mass analyzer 35. 
1.4.2.2 Linear quadrupole ion trap (LTQ) 
The linear quadrupole ion trap can be used in various applications such as protein 
identification and quantitative differential expression analysis, biomarker studies and PTM 
identification, metabolite identification and quantification, drug screening etc. The basic 
construction of a commercial LTQ contains two pairs of orthogonal hyperbolic rods, each 
segmented into three sections, with the length of the central section is about three times larger 
than the two end sections. There are two small slits along the rods at the Z axis to allow ions 
to be scanned out of the trap. Two detectors are placed symmetrically towards the slits to 
record the radially ejected ions. Direct current (DC) voltages are applied to three sections 
allowing trapping of the ions along the axis in the central part (figure 6).  
 
 
 
 
 
Figure 6. Basic structure of the two‐dimensional linear ion trap. Image adapted from Schwartz J C et 
al., Journal of the American Society for Mass Spectrometry, 2002. 
 
In a linear ion trap, injected ions are confined radially (x- and y- directions) by a two 
dimensional radio frequency (RF) field, and axially by stopping potentials applied to the end 
electrodes. The two pairs of opposing rods receive the same voltages, but neighboring rods 
have opposite voltages but with the same amplitude. Along the z- axis, different DC voltages 
are applied to the three sections to generate a deep electric potential well in the central section 
for ion trapping in the axial direction. In addition, a supplemental alternating current (AC) 
voltage across the x rods is applied to assist ion isolation, activation and ejection 36. 
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 Once in the trap, the ions are cooled by collision with an inert gas and fly along the z-
axis between the end electrodes, while simultaneously oscillating in the xy plane owing to the 
application of the RF potential on the rods37. Importantly, the ion oscillation frequencies in 
the radial and axial directions depend on the mass-to-charge ratios, so ions can be specifically 
fragmented or ejected by applying the corresponding RF resonance frequencies to the trap.  
The analyzer is scanned by applying RF at a fixed frequency but with variable amplitudes. 
For analyzing trapped ions, the mass-selective instability principle is employed where the 
primary RF voltage increases at a constant rate. Under the two-dimensional electric field the 
ions are pushed and pulled in the x- and y-directions as they travel along the z-axis, this 
process filters out ions of all m/z values except for those of interest. The ramping of the RF 
potential amplitude causes all ions to eventually exceed the resonance ejection limit and be 
ejected through the exit slits in the x-rods to the detectors placed right beyond the slots, to 
provide maximum sensitivity36, 38. In this way, ions with specific mass to charge ratio can be 
isolated and ejected from the trap. 
The LTQ can perform MS analysis alone or be connected with other analyzers as a 
hybrid mass spectrometer. The mass accuracy of LTQ can be up to 50 ppm and resolution 
close to 1000 (m/z 400, at an ion target value of 5000) 39. Compared to a conventional 3D ion 
trap, LTQ has an increased ion storage capacity (15 times higher), improved ion trapping 
efficiency (up to 70%), high detection efficiency (up to 100%) and better scan rate (3 times 
faster) 36.  
1.4.2.3 Orbitrap 
      The Orbitrap is the most recent type of ion trap mass analyzer. It uses an electrostatic field 
to trap ions instead of a RF or magnet field. The Orbitrap consists of an outer barrel-like 
electrode and a coaxial inner spindle-like electrode (figure 7). The outer electrode is split at 
the middle allowing ions to be injected into the trap. The two electrodes generate a static, 
quadro-logarithmic electrostatic field. The ions enter the electric field between the two 
electrodes in a tangential way, and they are trapped because of their electrostatic attraction to 
the inner electrode is balanced by centrifugal forces. The ions cycle around in circles and also 
move back and forward along the axis. 
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Figure 7. A cut‐away model of the orbitrap mass analyzer. From Scigelova M. et al., Proteomics, 2006. 
The frequency of the oscillations of the ions is proportional to the square root of the 
mass-to-charge ratio but is completely independent of the energy and the spatial spread of the 
ions 40. By sensing the ion oscillation frequencies using Fourier transformation, the trap can 
be used as a mass analyzer. The Orbitrap can provide very high mass accuracy (1-2 ppm) and 
mass resolution (up to 200,000) 41, 42. 
1.4.2.4 LTQ-Orbitrap Hybrid Mass Spectrometer  
The LTQ-Orbitrap is widely used in MS-based proteomics studies. Produced by Thermo 
Fisher, the LTQ-Orbitrap combines the advantages of fast scanning rate and high sensitivity 
of the LTQ and the advantages of high mass accuracy, high resolution and high dynamic 
range of the Obitrap 43. MS related experiments in this thesis were all performed on a LTQ-
Orbitrap. 
The Linear ion trap is placed in front of the Orbitrap (figure 8), which detects MS and 
MSn with very high sensitivity but relatively low resolution and mass accuracy. Ions injected 
from the ESI source at first scanned in the LTQ to determine the ion current within the mass 
range of interest. This allows storing a user-defined number of ions 43. Accumulated ions can 
be transferred into an RF-only quadrupole called C-trap. The C-trap accumulates and stores 
the ions. The additional storage improves the analytical capabilities considerably 31. After 
leaving the C-trap, the ions are accelerated to high kinetic energies and pass through a small 
entrance aperture and enter the Orbitrap tangentially 42. Ions are captured in the Orbitrap by 
rapidly increasing the electric field. Signals from each of the Orbitrap outer electrodes are 
amplified by a differential amplifier and transformed into a frequency spectrum by fast 
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Fourier transformation. The frequency spectrum is converted into a mass spectrum and 
processed with Xcalibur software 43. 
 
 
 
 
 
 
Figure 8. A schematic of the LTQ Orbitrap. From Scigelova M et al., Proteomics, 2006. 
 
1.4.3 MS-based Quantitative Proteomics 
Many biological processes are triggered and regulated not only by turning protein 
expression on and off. Protein expression levels and their dynamic changes are also essential 
for various cellular activities. Therefore, it is not always sufficient to only identify proteins to 
decipher different biological phenomena. Precise quantification of protein expression and 
their modifications are of great demand for biological research. 
Traditionally, quantitative proteomics utilizes dyes, fluorophores or radioactivity. In 
MS-based proteomics quantification, established methods can be classified as metabolic 
labeling, chemical and enzymatic labeling, label free strategies and absolute quantitation 44, 45. 
General MS-based quantification workflows are illustrated in figure 9. 
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Figure 9. General MS‐based quantitative proteomics workflows. Boxes  in blue and yellow represent 
two  experimental  conditions. Horizontal  lines  indicate when  samples  are  combined. Dashed  lines 
indicate points at which experimental  variation and  thus quantification errors  can occur. Adapted 
from Bantscheff M et al., Analytical and bioanalytical chemistry, 2007. 
Metabolic labeling introduces a stable isotope signature into proteins at the early stages 
of protein expression. Labeled proteins with stable isotopes thus have shifted m/z values in 
mass spectra compared to their natural, non-labeled counterparts but are otherwise identical in 
all respects. Metabolic labeling allows mixing of labeled/unlabeled samples at the level of 
intact cells, which avoids accumulating systematic errors and inaccurate quantitation results. 
Stable isotope labeling by amino acid in cell culture (SILAC) is currently the most widely 
used method in metabolic labeling (detailed description in 1.4.3.1). 
Labeling of proteins or peptides after biosynthesis is often performed by in-vitro 
enzymatic or chemical labeling. Enzymatic labeling incorporates 18O molecules onto the C-
termini of peptides during protein digestion. This results for most proteases in a 4 Da mass 
difference between labeled and unlabeled peptides 46, 47. Chemical labeling can be performed 
both at intact protein or peptide level. Most often used methods include isotope-coded affinity 
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tags (ICAT) 48, isotope tags for relative and absolute quantification (iTRAQ) 49, 50, isotope-
coded protein label (ICPL) 51 and HysTag 52. 
Label free quantification is an emerging method: it compares the mass spectrometric 
signal intensity of peptides precursor ions belonging to a protein or the numbers of fragment 
spectra identifying a given protein between two biological samples 45. The method demands 
very precise and accurate performance of sample-preparation and analytical systems 53. 
Absolute quantitation can be achieved by spiking known amount of a standard reference into 
samples to be analyzed. Several methods are available for different applications, such as 
culture-derived isotope tags (CDITs) 54 and absolute quantitation (AQUA) 55. 
1.4.3.1 Stable Isotope labeling by amino acid in cell culture (SILAC) 
Using the SILAC method, based on labeling differences, up to three biological 
conditions can be directly compared in a single experiment. One population is fed with 
growth medium containing normal amino acids whereas the other one or two are fed with 
media supplemented with amino acids labeled with certain heavy isotopes. SILAC in 
combination with tryptic digestion often uses labeled arginine and lysine since trypsin 
predominantly cleaves peptide chains at the carboxyl side of lysine and arginine, thus 
allowing the relative quantitation of virtually all detected peptides. The most commonly used 
labeled forms are 13C6-Arg, 13C615N4-Arg, 2H4-Lys and 13C615N2-Lys. 44, 56, 57. 
Taking13C615N2-Lys and 13C615N4-Arg labeling as an example, the light form of cells are 
grown with normal amino acids whereas the heavy labeled cells are fed with13C615N2-Lys and 
13C615N4-Arg containing medium (figure 10). This results in 8 Da and 10 Da mass shifts for 
each lysine and arginine in the detected peptides, respectively. Light and heavy peptides co-
elute from liquid chromatography column (heavier peptides containing deuterium atoms elute 
earlier than their unlabeled counterparts 58, 59). The quantitation is done by comparing the 
extracted ion current (XIC) of two peptides, which is proportional to the peptide abundance 
(figure 11). 
In a cell-line dependent manner, the SILAC accuracy can be compromised by metabolic 
conversion of arginine to proline. This results in the formation of multiple satellite peak 
clusters for all proline containing peptides in the labeled states and thus hampers accurate 
quantitation60, 61. Solutions include empirically reducing the amount of arginine used in the 
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labeling media, mathematical corrections for all proline-containing peptides62, providing extra 
proline in media63, or internal correction strategies61. 
 
 
 
 
 
 
 
 
Figure 10. Outline of a double SILAC experimental workflow  
SILAC has proven to be a powerful quantitative method in many biological research 
fields, such as cell signaling 64, protein-protein interaction 65, protein phosphorylation 66 and 
gene function analyses67. The limitation of SILAC is that it is not feasible for in vivo tissue 
sample applications of large mammals.  
 
 
 
 
 
Figure 11. (A) MS spectra of isotope clusters of a SILAC peptide pair. (B) Extracted ion chromatogram 
of  co‐eluted SILAC peptide pair  from HPLC column. Adapted  from Ong S E et al., Nature Chemical 
Biology, 2005 
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1.4.4 Phosphoproteomics 
Reversible phosphorylation of proteins is among the most widespread post-translational 
modifications in eukaryotic cells. It regulates many biological processes such as signal 
transduction, cell division, gene expression, molecular recognition. It has been estimated that 
about 30% of the proteome is affected by phosphorylation at a given time point 64, 68, 69. 
Therefore, in-depth studies on protein phosphorylation are of great importance to help us to 
better understand diverse biological phenomena. However, complete phosphorylation 
profiling still remains a challenge due to its frequently low stoichiometry. Often only a few 
percent of the entire protein amount is present in the phosphorylated form 70.  
Traditionally, radioactive 32P-labeling coupled with 2D gel-electrophoresis and Edman 
sequencing was widely used to characterize phosphorylation on proteins. Western blotting 
using phospho-antibodies also has high sensitivity and specificity for detecting specific 
phosphorylation sites.   
Nowadays, mass spectrometry has become the most powerful and popular method in the 
field of phosphoproteomics. Generally, target proteins are in-solution or in-gel digested 
before phosphopeptides are isolated from highly complex peptide mixtures and subjected to 
mass spectrometry analysis. A comprehensive phosphorylation profiling should include the 
identification of phosphorylated peptides, and the exact localization of the phosphorylated 
amino acids within the peptide sequences.  
The ability of performing phosphoproteomics is highly dependent on effectively 
isolating phosphorylated peptides from non-phosphorylated species. There are many 
developed enrichment strategies such as TiO2, strong cation exchange chromatography 
(SCX), immobilized metal affinity chromatography (IMAC), ZrO2 71 etc. Projects described in 
this thesis are based on TiO2 and SCX as phosphorylated peptide enrichment methods. 
1.4.4.1 TiO2 phosphorylated peptide enrichment  
Titanium dioxide (TiO2) beads have specific affinity to organic phosphates in solution. 
Additionally, their high mechanical, chemical and thermal stability facilitates their use to 
selectively enrich phosphorylated peptides from complex mixtures. Very high enrichment 
efficiencies (> 90%) in low-complexity samples have been reported 72. In large-scale 
phosphoproteomics, unspecific binding of non-phosphorylated peptides and acidic peptides to 
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TiO2 beads become severe. Loading peptide mixture to TiO2 in organic solvent with strong 
acid and “non-phosphorylated peptide excluder” as a modifier can significantly increase 
enrichment selectivity. The “non-phosphorylated peptide excluders” should be able to 
compete with the binding of non-phosphorylated peptides to TiO2 and 2,5-dihydroxy benzoic 
acid (DHB), phthalic acid, glycolic acid, and lactic acid have proven to be efficient additives 
73, 74. 
1.4.4.2 SCX phosphorylated peptide enrichment 
SCX often uses silica-based materials with bonded coating of hydrophilic, anionic 
polymer to selectively separate phosphorylated peptides from non-phosphorylated ones based 
on their charges. Between pH 2.7-3.0, which is used in the SCX loading buffer, most tryptic 
peptides carry at least two positive charges 75. Because of added negatively charged phosphate 
groups, phosphorylated peptides will have reduced numbers of positive net charges, and 
therefore exhibit weak or no binding to the SCX separation column, while non-
phosphorylated peptides bind usually stronger. However, the interfering effect from acidic 
peptides has not yet been overcome in this strategy. SCX is a robust phosphorylated peptide 
enrichment method but with modest enrichment efficiency 75, 76.
 5 
2 Aims of this study 
The mitotic spindle is essential for accurate chromosome segregation during cell 
division. Reversible protein phosphorylation is a key regulatory mechanism involved in the 
formation and regulation of spindles. Insight into the phosphorylation network of spindle 
proteins is of great interest for us to gain a better understanding of the regulation and function 
of the mitotic spindle.  
The Plk1 substrate identification part of this thesis aims at identifying the specific 
phosphorylation substrates of a key mitosis regulator, Polo-like kinase 1, on human mitotic 
spindles, and to explore the role of this kinase in the phosphorylation network of the spindle 
associated proteins. 
The evaluation of the use of elastase project aims at combining the use of the specific 
enzyme trypsin and the low specificity enzyme elastase to achieve a better sequence coverage 
for the phosphoproteomics study of human mitotic spindles.  
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3 Results 
3.1 Quantitative identification of Polo-like kinase 1 (Plk1) specific 
phosphorylation sites on human mitotic spindle proteins 
3.1.1 Introduction 
        In mitosis, a eukaryotic cell separates the chromosomes into two identical sets in two 
daughter cells. A series of tasks such as mitotic entry, spindle assembly, chromosome 
segregation, and cytokinesis, must be carefully coordinated to ensure the error-free 
distribution of chromosomes into the newly forming daughter cells. The physical separation 
of the chromosomes to opposite poles of the cell is driven by the mitotic spindle, a highly 
dynamic microtubule (MT)-based, protein-associated macromolecular machine. Spindle 
assembly begins early in mitosis and is completed when bipolar attachment of microtubules to 
kinetochore pairs occurs 77, 78. Polo-like kinase 1 (Plk1), a serine/threonine-specific kinase 
first identified in Drosophila 79, is a key regulator of this essential mitotic process 13, 14.  
        Plk1 has diverse functions and it’s localization during mitosis is dynamic. Plk1 first 
associates with centrosomes in prophase, then associates with the spindle poles and 
kinetochores (KTs) in prometaphase and metaphase, is recruited to the central spindle in 
anaphase, and finally accumulates at the midbody during telophase. Proteomics studies using 
oriented peptide libraries suggest that the two polo-box domains (PBDs) of Plk1 are crucial 
for its localization to cellular structures 15. These domains bind to specific amino acid 
sequence motives which were phosphorylated by priming kinases or self-primed by Plk1, thus 
providing an efficient mechanism to regulate localization and substrate selectivity in time and 
space. 
Plk1 has fundamental roles in early mitosis in centrosome maturation, kinetochore-
microtubule attachments and spindle assembly, but to date only a limited number of targeted 
proteins and phosphorylation sites on these substrates have been conclusively identified 12, 80. 
Moreover, the current understanding of the functions of these site-specific Plk1 
phosphorylations is far from being complete, in part due to low abundance of the substrates, 
technical difficulties in determining in vivo phosphorylation sites, and the requirement of Plk1 
localization for substrate recognition in some of the cases 81. 
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        In recent years, mass spectrometry (MS) has become a key technology for mapping 
protein phosphorylation sites. The optimization of methods for enriching and detecting 
phosphorylated peptides have shown great promise for large scale studies 82. Previously, we 
explored the human mitotic spindle by MS and successfully identified a large number of 
novel spindle proteins and phosphorylation sites 83, 84. The development of quantitative 
methods to monitor in vivo phosphorylation changes in complex samples 64, 85, represents a 
unique opportunity to address the role of individual kinases in spindle function.  
In this work, we performed quantitative analysis for human mitotic spindle proteins 
using SILAC in combination with a phosphopeptide enrichment approach. Aimed at 
improving our current experimental coverage of Plk1 substrates and gaining insight into the 
direct and indirect effects of Plk1, we have analyzed how reduced Plk1 activity affects the 
phosphoproteome of purified human mitotic spindles. We report the combination of the 
selective inhibition of Plk1 using either an inducible Plk1 depletion shRNA cell line or the 
small molecule inhibitor TAL 86. The experimental strategy was applied to analyze Plk1 
phosphorylation on spindle proteins at an early mitosis stage. Furthermore, we set out to 
validate the phosphorylation sites found to be down-regulated in the absence of Plk1 activity 
using in vitro phosphorylation assays on peptide spots arrays.  
Our approach identified novel Plk1 substrates and validated more than 100 in vivo direct 
Plk1 phosphorylation sites. By probing a large set of candidate Plk1 peptides, we were able to 
broaden the consensus phosphorylation motif of this kinase. Moreover, we showed that the 
Plk1-dependent localization of some of the identified protein substrates to the centrosomes 
and kinetochores. In addition, we could confirm that the Aurora A signaling pathway is 
downstream of Plk1. 
 
I emphasize that major biological experiments (cell culture, spindle isolation, IF, western 
blotting etc.) in the Plk1 substrate identification project of this thesis were performed by Dr. 
Anna Santamaria (MPIB). The results are shown here in order to confer biological relevance 
to the proteomics analysis that was carried out by myself. The in vitro kinase assay 
experiments were performed by Dr. Sabine Elowe (MPIB).  
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3.1.2 Experimental design for the comparison of the spindle 
phosphoproteome between cells in the presence or absence of 
Plk1 
 To gain insight of the phosphoproteomes of human mitotic spindles from Plk1-inhibited 
cells with spindles from control cells with fully active Plk1, we developed a quantitative 
phosphoproteomics strategy that combines SILAC with selective enrichment of spindle-
associated proteins by isolating human mitotic spindles (figure 12).  
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Figure 12. Schematic of the experimental design for the SILAC experiments. (A) HeLa S3 cells grown 
in  the presence of normal or  stable  isotope‐labeled arginine  and  lysine were  synchronized by Tet 
induction  and MA/TAL  treatment,  respectively.  (B, C) DNA  and/or  spindle morphology of MA  and 
TAL‐treated cells (DAPI staining is shown) and shEg5 and shPlk1‐induced cells (α‐Tubulin is shown in 
green and DNA was visualized using DAPI  (blue)) prior  to mixture and  spindle  isolation.  (D, E) DIC 
pictures of isolated mitotic spindles. Scale bar, 10 μm. (F) Analytical strategy to map phosphorylation 
sites in spindle proteins. (G) Validation of direct Plk1 phosphorylation sites by peptide spotting and in 
vitro Plk1 kinase assays.  
 
        To synchronize control cells to the same mitotic stage and importantly, obtain similar 
microtubule arrays as in Plk1-inactivated cells, we interfered with the function of the kinesin 
motor protein Eg5. Similar to Plk1 inactivation 87, Eg5 inhibition results in a prometaphase 
arrest with a monoastral microtubule array surrounded by a ring of chromosomes 88. 
Importantly, Plk1 localization and kinase activity were retained in Eg5-inactivated cells, 
supporting the use of Eg5 as control (figure 13) 86. 
 
Figure 13. (A) Lysates from CTL, shEg5 and shPlk1 cells treated for 36 h with Tet or left for 36 h in Tet‐
free medium,  treated  for  the  last 12 h with nocodazole,  to obtain cells  in  the  same mitotic stage. 
Membranes  were  probed  for  Eg5,  Plk1,  BubR1,  Cyclin  B1  and  α‐Tubulin,  as  loading  control.  (B) 
DMSO, MA‐treated cells were fixed and stained for the indicated antibodies. Plk1 is shown in red and 
CREST in green. DNA was visualized using DAPI (blue). Scale bar is 10 μm (experiment performed by 
Dr. Anna Santamaria).  
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         We employed two different experimental strategies. First, we interfered with Plk1 
function by lowering Plk1 protein levels. To do this systematically, we generated tetracycline 
(Tet) inducible stable HeLa S3 cell lines for shRNA-mediated knockdown of Plk1 and Eg5, 
as control (shPlk1 and shEg5 cell line, respectively). After shRNA induction, Eg5 and Plk1 
protein levels were efficiently reduced when compared to non-induced or control cells (a 
stable cell line generated with an empty vector driving non specific shRNA expression; CTL 
cells) (figure 13A and 14A). Consistently, depletion of Plk1 but not Eg5 led to loss of BubR1 
hyperphosphorylation (figure 13A), which was shown to be Plk1 dependent 89-91. Flow 
cytometry (FACS) analysis of Tet-induced shEg5 or shPlk1 cells revealed an accumulation of 
cells with a 4N DNA content, indicative of a G2/M arrest (data not shown). Concomitantly, a 
striking increase in the mitotic index could be observed, in agreement with the predominant 
phenotype seen upon interference with Plk1 or Eg5 87, 88.         
        Analysis of the protein levels of Plk1 and Eg5 upon Tet induction by MS in the 
appropriate shRNA cell line provided an independent assessment for depletion efficiency in 
our shRNA cell lines (figure 14B and C). 
As a second complementary strategy, a chemical biology based approach using the 
specific small molecule Plk1 inhibitor TAL 86 was employed to directly interfere with the 
enzymatic activity (rather that protein levels) of Plk1. Monastrol (MA), a small molecule 
inhibitor of Eg5 92, was used to treat control cells (figure 12B and 13B). 
Two independent experiments were performed for each Plk1 inactivation strategy which 
served as biological replicates.  
To enable accurate quantitation of the changes of phosphorylated peptide abundances by 
MS, cells were labeled by growing them in medium containing either normal arginine and 
lysine (Arg0/Lys0) or the heavy isotopic variants 13C6-15N4-arginine and 13C6-15N2-lysine 
(Arg10/Lys8) 44. In three of the four experiments shPlk1 or TAL-treated cells were grown in 
SILAC medium supplemented with light amino acids, whereas shEg5 or MA-treated cells 
were grown in SILAC medium supplemented with heavy amino acids, whereas an additional 
experiment was performed under reverse labeling condition (experiment Inhibitor-1). 
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Figure 14.  (A) shEg5 and shPlk1 cells  treated  for 36 h with Tet or  left  for 36 h  in Tet‐free medium 
were fixed and stained for the indicated antibodies. Eg5 and Plk1 are shown in green and α‐Tubulin 
in red. DNA was visualized using DAPI (blue). Scale bar is 10 μm. (experiment performed by Dr. Anna 
Santamaria, MPIB)  (B) Mass  spectra  representing a SILAC peak‐pair  for Plk1 and Eg5,  respectively, 
from shEg5/shPlk1‐induced cells. 
 
        Taxol-stabilized mitotic spindles (containing KTs and centrosomes) were purified 
essentially as previously described 93. To ensure minimal variation in sample handling and 
processing, equal amounts of Plk1 and Eg5-depleted/inhibited cells were combined prior to 
spindle isolation (figure 12A-C). Examination of the purified spindles by differential 
interference contrast (DIC) light microscopy revealed predominantly monopolar spindles 
(Figure 12D, E), as expected, largely free of other cellular structures.  
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Purified spindles were subsequently solubilized and separated by one-dimensional SDS-
PAGE gradient gel electrophoresis.  The gel was then cut into 16-20 slices, covering all 
spindle protein mass ranges (Figure 12F). Spindle Proteins were digested in-gel with trypsin 
and the resulting peptide fractions were subjected to phosphorylated peptide enrichment on 
TiO2 beads prior to analysis of both TiO2-elution and TiO2-flow-through fractions 
(phosphorylated and unphosphorylated peptides, respectively), using a nanoLC-LTQ-Orbitrap 
system. 
3.1.3 Plk1-dependent human mitotic spindle proteome and 
phosphoproteome 
        From 226 LC-MS/MS runs for proteome and phosphoproteome quantification, we 
identified 3395 unique proteins at a false discovery rate (FDR) of 2%. About 60% of the 
proteome (1996 proteins) was phosphorylated, and more than 90% (3108) of identified 
proteins had quantification profiles (i.e. could be quantified with SILAC). The 
phosphorylation output file of MaxQuant contained 9544 phosphopeptides. However, this list 
still contains phosphopeptides with low identification Mascot score and duplicates in the form 
of phosphorylation-isoforms, for which the exact site of phosphorylation within the peptide 
sequence could not be determined.  
        After applying a Mascot score cut-off ≥ 12 for all assigned phosphorylated peptides and 
a phosphorylation site localization probability score cut-off ≥ 0.75 (class I sites) 64, 4420 
unique phosphorylation sites with high confidence were identified at a false-discovery rate 
(FDR) of 0.89% from 4 different experiments (3526 from inhibitor experiments and 3212 
from shRNA experiments). Distributions of phosphoserine (79.8%), phosphothreonine 
(19.6%) and phosphotyrosine (0.6%) sites (localization probability > 0.75 64), resembled the 
ones reported in an independent quantitative analysis of the human spindle phosphoproteome 
at distinct mitotic stages 94.           
        To control for fluctuations in levels of individual proteins between the different 
experimental conditions, all measured phosphorylated peptide ratios were normalized against 
the levels of the protein in question.  
         Collectively, these analyses led to a final number of 3894 unique phosphorylation sites 
with SILAC and corresponding protein ratios, including 3092 and 2808 phosphorylation sites 
from experiments performed with small molecule inhibitors and the shRNA cell lines. Key 
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features of the identified phosphoproteome are summarized in figure 15. 
 
 
 
 
 
 
 
                                         
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  A phosphoproteome data processing work‐flow for the detection of Plk1‐dependent 
phosphorylation sites in isolated mitotic spindles. 
 
 
 
3.1.4 Plk1-dependent quantitative human mitotic spindle 
phosphoproteome 
        To describe changes in phosphorylation upon Plk1 inactivation, an independent small 
scale pilot experiment was performed to determine a threshold for significant phosphorylation 
regulation. TAL was applied to SILAC light and heavy-labeled HeLa S3 cells, respectively. 
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Mitotic cells were combined 1:1 and the sample analyzed by MS (1612 phosphorylation sites 
were identified with high confidence). The error rates for normalized ratios with significance 
threshold < 2/3 and > 3/2 were 4.4% and 1.9%, respectively.  
        We applied this threshold to our Plk1 experiments. In three out of four experiments, the 
Plk1 inhibited samples was light labeled and ratios > 3/2 were considered as significant, and 
in the fourth experiment, Plk1 inhibited sample was heavy labeled and ratios < 2/3 were 
considered as significant. Thus, the average quantitation error in our combined dataset can be 
estimated as (3×1.9%+4.4%)/4, resulting in 2.5%. The selected quantitative change above 
50% as significant for regulated phosphorylation events is also in line with other recent 
SILAC based studies67, 95-97. Furthermore, since our experimental strategy includes a 
downstream in vitro kinase assay for the verification of potential Plk1 direct targets, we 
consider this error rate as a good compromise between experimental sensitivity and 
stringency.  
        Based on the chosen ratios of > 1.5 (3/2) and < 0.66 (2/3) as thresholds for considering 
any observed change as significant, the automated quantification was accomplished by 
MaxQuant software. The ratios of each ion pair with different SILAC labeling were 
normalized by corresponding protein expression levels which were quantified only with 
unphosphorylated peptides.  
         A total of 702 phosphorylation sites were identified as down-regulated in at least one of 
the four experiments, 527 sites after TAL treatment and 268 sites after Plk1 depletion by 
shRNA (figure 15), with an overlap of 93 sites (figure 16B).  
         Between replicate experiments, a few phosphorylation sites with inconsistent trends 
(sites down-regulated in one experiment but up-regulated in the corresponding biological 
replicate) were excluded from further analysis. For the remaining sites (the vast majority), the 
overlaps of identified phosphorylation sites between two strategies and biological replicate 
experiments are listed in figure 16A.   
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Figure  16.  Comparative  assessment  of  phosphoproteomics  data.  (A)  Venn  diagrams  illustrating 
overlap  of  the  phosphorylation  sites  identified  in  this  study.  Overlap  between  the  two  different 
strategies  (upper diagram)  and  the  two biological  replicates  from  inhibitor or  shRNA experiments 
(middle  and  lower  diagram,  respectively)  are  shown.  (B)  Overlap  of  the  down‐regulated 
phosphorylation sites identified from two approaches.  
 
        As an example for the quantification of SILAC pairs of phosphorylated peptides, the MS 
spectra of the kinesin KIF4A identified in experiments performed with both the shRNA cell 
lines and small molecule inhibitors are shown in figure 17. 
 
 
 
 
 
 
 
 
 
 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  17.  SILAC  KiF4A  phosphorylated peptides.  Four  independent  experiments were  carried out 
with different SILAC  conditions. Due  to  the SILAC  strategy  for metabolic  labeling, arginine‐ and/or 
lysine‐containing peptides co‐eluted  in  LC‐MS as doublets with a defined mass difference. The  ion 
signals allowed accurate measurement of relative peptide abundance. Representative MS spectra of 
a KIF4A phosphorylated peptides following the classical Plk1 consensus motif quantified on spindles 
isolated from MA/TAL‐treated cells (A) and shEg5/shPlk1‐induced cells (B). Measured and normalized 
peptide  ratios  are  shown.  (C‐E)  Representative  MS  spectra  of  a  KIF4A  phosphorylated  peptide 
containing an N in position ‐2, quantified on spindles isolated from MA/TAL‐treated cells (C and D) or 
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shEg5/shPlk1‐induced cells (E). Reciprocal SILAC labeling in experiments shown in C and D resulted in 
inversed  peptide  ratios  in  the MS  spectra  (crossover  experiment). MaxQuant  assigned  the  same 
phosphorylation  site  within  the  peptide  with  high  confidence  (localization  probability  score  1). 
Measured and normalized peptide ratios are shown.  
To address the reproducibility of phosphorylation site identification and quantification, 
half of the purified spindle protein sample from one of the experiments, performed with the 
Tet-inducible stable cell lines, was separated on a distinct 1D gel and subsequently analyzed 
as a technical replicate. A good reproducibility (r2-value: 0.84) was observed (figure 18), in 
line with other recent phosphoproteome studies 85, 98.  
 
 
 
 
 
 
 
 
Figure  18.  Reproducibility  of  phosphorylated  peptides  SILAC  abundance measurements.  Enriched 
spindle  proteins  from  20  gel  slices  of  one  RNAi  experiment  were  analyzed  twice  in  LC‐MS/MS, 
datasets named  as RNAi 2b1 and RNAi 2b2.  For  SILAC phosphorylated peptides  identified  in both 
datasets, the log transformed abundance ratios (H/L) from RNAi 2b1 were plotted against that from 
RNAi 2b2 (1236 unique phosphorylation sites). 
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3.1.5 Plk1 spindle substrates identification 
        There were 360 candidates of down-regulated phosphorylation sites quantified on 
spindle proteins upon Plk1 inactivation, either by TAL-treatment or stable shPlk1-mediated 
depletion (figure 15 and appendix, note: 68 sites were included regardless of low localization 
probability threshold for further in vitro kinase assays). Importantly, the majority (63%) of 
those down regulated phosphorylation had not been reported earlier.   
        In agreement with essential functions of Plk1 at the spindle poles, centrosomal and MT-
associated proteins (MAPs), as well as motor proteins, were identified upon Plk1 inactivation 
(figure 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Plk1‐dependent substrates on the mitotic spindle. The pie chart depicts proteins showing 
down‐regulated  phosphorylation  sites  upon  Plk1  inactivation.  They  are  classified  into  categories 
based on either function or localization. Known Plk1 substrates are shown in bold.  
3.1.6 Validation of Plk1-dependent phosphorylation sites on spindle 
proteins through a candidate-based in vitro kinase screening 
        As a consequence of reduced Plk1 activity, phosphorylation sites on direct Plk1 
substrates are expected to be down-regulated in Plk1-depleted or TAL-treated cells. However, 
considering that kinases and phosphatases often form complex signaling networks, the pool of 
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regulated phosphorylation sites is also expected to include indirect targets of Plk1 activity, 
notably proteins that are targets of kinases or phosphatases that act downstream of Plk1. 
         To distinguish direct from indirect substrates of Plk1 activity, we used a peptide spotting 
approach to validate potential direct Plk1 phosphorylation sites (experiments performed by 
Dr. Sabine Elowe, MPIB). Using peptides synthesized directly on cellulose membranes as 
substrates, we performed in vitro Plk1 kinase assays with recombinant Plk1 purified from 
insect cells (figure 12G). All down-regulated phosphorylation sites on spindle components 
were arrayed on the membrane as 12-mer peptides, with the potential phosphoacceptor amino 
acid kept constant at position 7 in either its serine/threonine/tyrosine native form or changed 
to alanine to verify signal specificity. Incubation of duplicate peptide arrays (generated 
simultaneously) with either kinase and [32P]-ATP or [32P]-ATP alone, followed by extensive 
washing, resulted in clear and specific signals on membranes phosphorylated by Plk1, 
whereas virtually no signal was detected on control membranes incubated with [32P]-ATP 
alone.  
        In total, 102 down-regulated sites (figure 15 and appendix) were verified as direct in 
vitro targets of Plk1 phosphorylation using this approach (table 1).  
 
Table 1. Plk1 phosphorylation sites on known spindle proteins 
Proteins Acc. Number Phosphorylation sites 
ARHGEF2 Q92974 S737 
ASPM Q8IZT6 T178, S267, S270, S280, S355, T356, S1825, 
S3426 
AURKB Q96GD4 Y239 
BLM P54132 S26*, S28* 
BUB1 O43683 S661 
CASC5 Q8NG31 S1013, S1808 
CDC27 P30260 S441 
CENPB P07199 S306, S307 
CENPC1 Q03188 S96, S104, S110, T231*, T516, S250, T734 
CENPE Q02224 S611, S112 
CENPF P49454 S242, S838, S1248, S1324, S1750, S2512, 
S2513 
CENPI Q92674 S709, S710
CENPJ (CPAP) Q9HC77 S556* 
CENPL Q8N0S6 S53 
CENPN Q96H22 S226, S235, S282
CENPT Q96BT3 S45 
CENPU (PBIP1) Q71F23 S194 
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C14Orf106 Q6P0N0 S135, S191, S192 
Cep97 Q8IW35 S308 
Cep170 Q5SW79 S880* 
Cep192 Q8TEP8 S1502 
Cep215 Q96SN8 S613, S1102 
Cep350 Q5VT06 S2689 
DGL7 (HURP) Q86T11 S777 
DSN1 Q9H410 S123 
ERCC6L (PICH) Q2NKX8 S774, S790 
INCENP Q9NQS7 S72, S330 
KIF18A Q8NI77 S681* 
KIF20A O95235 Y558, S635 
KIF23 Q02241 S867*, S889 
KIFC1 (HSET) Q9BW19 S33 
KIF4A O95239 S815, S951 
MAD1L1 Q9Y6D9 S8*, S490*
NCAPD3 P42695 T430, S508 
NCAPG2 Q86XI2 S30, T1114 
NCAPH Q15003 T98
NPM P06748 S198 
NuMA Q14980 T1818 
Nup93 Q8N1F7 S72 
Nup98 P52948 S591 
Nup107 P57740 S4,S57 
Nup153 P49790 S343 
Nup188 Q5SRE5 S1523 
PCM1 Q15154 S110 
PCNT O95613 S554, S813, S815, T1690, S2594, T3325, 
S3326   
PRC1 O43663 S554 
RACGAP1 Q9H0H5 S164, S170, S214 
SGOL2 O562F6 S436, S1151* 
SON P18583 S154, T2022 
SPAG5 (ASTRIN) Q96R06 S401 
TOP2A P11388 S285 
TPR P12270 S1185
TPX2 Q9ULW0 S356, T361, S654 
TUBA1C Q9BQE3 S48, T51 
TUBGCP5 Q96RT8 S182 
Vimentin P08670 S83, S409, T458, S459 
ZWINT O95229 S84* 
          * sites found in pilot experiments and in this study but excluded from the appendix  
              due to Mascot score < 12 or contradictory ratio between inhibitor or cell lines experiments. 
              Known Plk1 substrates and phosphorylation sites are marked in bold. 
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3.1.7  Reconsideration of the Plk1 consensus motif 
     Analysis of the in vitro verified Plk1 sites using the Motif-X software tool (established in 
collaboration with Dr. Rainer Malik, MPIB), revealed many peptides that conform to the 
general Plk1 kinase consensus motif  D/E-X-S/T-Φ (where X is any amino acid and Φ 
corresponds to a hydrophobic amino acid) (appendix) 81. Interestingly, the percentage of 
positive peptides containing a glutamine (Q) in -2 position was comparable to the one 
observed on peptides that conformed to the classical Plk1 consensus motif (59% and 56%, 
respectively) (appendix). Furthermore, an asparagine (N) in -2 position was also observed in a 
large number (58%) of the in vitro validated Plk1 phosphorylation sites, and we note that an 
N at the -2 position has previously been reported in a number of in vivo substrates of Plk1 or 
its yeast homolog Cdc5p, including  the APC subunit Cdc27 149, the cohesion subunit Rec8 
150, the cytokinesis effector kinase Rock2 151 and the centralspindlin complex component 
MgcRacGAP 152. Furthermore, N, E and D at the -2 position occurred with similar frequency 
in our set of validated sites, suggesting that an N at the -2 position is prevalent in the target 
sequence of a broad range of in vivo Plk1 substrates.   
        To further explore the optimal Plk1 consensus motif, an in vitro kinase assay was 
performed to screen for Plk1 phosphorylation on the CENP-F peptide containing S1324 
(experiment performed by Dr. Sabine Elowe, data not shown). Originally, the peptide 
contained an N at the -2 position. Each residue from positions -4 to +2 was substituted with 
every other natural amino acid, and the ability of Plk1 to phosphorylate the resulting peptides 
was analyzed in an in vitro phosphorylation assay. The results clearly demonstrate a strong 
preference of Plk1 for particular residues N-terminal to the phosphoacceptor amino acid; 
instead, virtually all amino acid substitutions were well tolerated at the +1 and +2 position, 
although there was also a clear preference for hydrophobic residues. A notable exception was 
proline at the +1 position, which was not tolerated. This strongly suggests that S/T-P motifs 
are not substrates for Plk1. Furthermore, we note the equal preference for N or E at the -2 
position. Significantly, a leucine in position -3 was prominent in many validated 
phosphorylated peptides and substitution of this residue in the CENP-F peptide screen was 
poorly accepted.  
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        Collectively, these observations are in agreement with both our MS data and the results 
of the peptide spotting screen. The data presented above suggest that the consensus sequence 
for Plk1 should be broadened to L(Φ)-E/N/D(Q)-X-S/T-(Φ). 
3.1.8 Plk1-dependent localization of spindle components 
        In accordance with the requirement for Plk1 activity to properly localize some of its 
substrates on the mitotic spindle 13, we considered it likely that the localization of some of its 
downstream targets would be altered as a consequence of Plk1 inhibition. To analyze this 
possibility in a systematic and quantitative manner, we prepared total lysates from cells grown 
in SILAC medium treated with either MA or TAL, and compared the SILAC ratios to the 
ones quantified in experiments with isolated spindles. 
        Proteins showing a reduced or increased association with the spindle apparatus are 
displayed in figure 20A (note that only proteins with SILAC ratios identified in both spindle 
and total lysate experiments are shown). Strikingly, upon Plk1 inactivation many proteins 
were depleted from the spindle and many contained down-regulated phosphorylation sites 
(figure 19 and appendix), arguing that Plk1 activity is required for their spindle localization.  
        Our MS analysis demonstrates that levels of the γ-Tubulin complex subunits and the 
centrosomal proteins pericentrin, Cep192, and Cep215 (PCM proteins implicated in 
centrosomal γ-Tubulin attachment 99), were also highly reduced upon Plk1 inhibition. 
Importantly, our study revealed novel Plk1-dependent phosphorylation events on these 
proteins that might contribute to their role in centrosome maturation and spindle assembly.  
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Figure 20. Plk1 dependent localization of spindle components. (A) Proteins with altered spindle levels 
upon  Plk1  inactivation  are  shown.  Known  Plk1  substrates  are  shown  in  bold.  Proteins  were 
subcategorized  according  to  their  relative  spindle  amount  from  0  to  1.7.  Ratio  =  1  indicates  no 
change  on  spindle  levels  relative  to  total  lysate  amounts.  Tubulin  subunits  used  to  normalize  all 
ratios are depicted in blue, whereas the control protein Eg5 (KIF11) with a ratio close to 1 is shown in 
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red. (B, C) Representative MS spectra of a CENP‐F phosphorylated peptide quantified on spindles (B) 
and total lysates (C) of MA/TAL‐treated cells. Measured, corrected and normalized peptide ratios are 
shown. (D) HeLa S3 cells treated with MA or TAL were fixed and immunostained for pS1324 CENP‐F 
(red), CENP‐F  (green) and CREST  (far  red, depicted  in blue). DNA was visualized using DAPI  (blue). 
Scale bar, 10 μm.  (E, F) Fluorescence  intensity of pS1324 on CENP‐F and CENP‐F, respectively, was 
quantified at KTs  in MA or TAL‐treated cells.  Intensities were plotted as a CENP‐F or pS1324 versus 
CREST ratio (10 cells/>10 KTs per cell, n= 3 independent experiments). Columns and error bars show 
average  and  standard deviation of 3  independent experiments.  (experiments  for  figures D‐F were 
performed by Dr. Anna Santamaria, MPIB) 
        An intriguing case was CENP-F, a large coiled-coil protein that transiently localizes to 
outer KTs, and preferentially to KTs of unaligned chromosomes 100. Although it was 
previously shown that CENP-F exhibits slower electrophoretic mobility upon mitotic entry 
101, very little is known about CENP-F phosphorylation. We identified 19 serine and threonine 
phosphorylation sites on CENP-F that were suppressed by more than 2-fold upon Plk1 
inhibition, 8 of which we could validate in vitro (table 1 and appendix). Collectively, these 
results identify CENP-F as a novel Plk1 substrate.   
        Our MS data further suggest that the levels of CENP-F on the spindle apparatus were 
reduced upon Plk1 inactivation when compared to the corresponding levels in total lysates 
(figure 20A-C). Immunofluorescence analysis also revealed a significant reduction of total 
CENP-F and CENP-F S1324 phosphorylation signal at KTs upon TAL treatment (figure 20D-
F). These data demonstrate that CENP-F localization is directly regulated by Plk1 
phosphorylation.  
3.1.9 Integration of Aurora A and Plk1 activity 
        Aurora A localization to centrosomes has also recently been shown to depend on Plk1 
activity 86, 102, 103. In agreement with this, our MS data shows that Aurora A levels on the 
isolated spindle were reduced by 50% upon Plk1 inhibition when normalized against the H/L 
ratio for Aurora A in total lysates (figure 21A and B). 
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Figure 21. Reduced Aurora A activity as consequence of Plk1  inactivation. (A, B) Representative MS 
spectra of an Aurora A phosphorylated peptide quantified from spindles (A) and total  lysates (B) of 
MA/TAL‐treated cells. Corrected and normalized peptide ratios are shown. (C‐E) Plk1 and Aurora A in 
vitro kinase assays. Kinases were  immunoprecipitated from MA/TAL treated cells and shEg5/shPlk1‐
induced  cells.  Casein  and  MBP  were  used  as  model  substrates  (D  and  E,  respectively).  Protein 
phosphorylation  is  visualized  by  autoradiography  [32P].  Total  cell  lysates  (Input,  C)  and 
immunoprecipitates  (D  and  E)  were  probed  by  Western  blotting  for  the  indicated  proteins 
(experiments for figures C‐E were performed by Dr. Anna Santamaria, MPIB)  
        It has also recently been postulated that Plk1 may contribute to efficient Aurora A 
activation 104, 105.  Indeed, when the two kinases were immunoprecipitated from either shPlk1-
depleted/TAL-treated cells or shEg5-depleted/MA-treated cells (for control) and then assayed 
in vitro on appropriate substrates (casein and myelin basic protein (MBP), respectively), both 
kinases showed strongly reduced activity (figure 21C-E).  While the reduction in activity was 
expected for Plk1, the significant reduction in activity observed in parallel for Aurora A 
strongly suggests that inhibition of Plk1 also reduces Aurora A activity.  
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        In further support of the above conclusion we emphasize that several of the 
phosphorylation sites identified as down-regulated after Plk1 depletion/inhibition by MS 
analysis conform to the Aurora A consensus motif 106, 107. Interestingly, many of these sites 
were present in proteins likely to be Aurora A substrates, including known Aurora A 
interactors such as TPX2 108 or centrosomal proteins and MAPs involved in centrosome 
maturation and spindle assembly.  
        Interestingly, we also identified substrates common to both Plk1 and Aurora A, such as 
pericentrin, the γ-Tubulin subunit GCP2, and the centrosomal protein Cep215, suggesting that 
these two kinases cooperate to control key early mitotic functions through co-regulation of 
several important substrates. Collectively, these observations support the idea that Aurora A is 
a downstream effector of Plk1 activity 105. 
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3.2 Phosphoproteome analysis of human mitotic spindle proteins by using 
low-specificity protease elastase 
3.2.1 Introduction 
Proteomics aims at the large scale characterization of the protein contents of complex 
biological systems 109, 110. As a result of improved mass accuracy, resolution, sensitivity, and 
speed, mass spectrometry has become a robust technique for proteome analysis 111-113. It 
allows not only the generation of comprehensive protein inventories, but also the large scale 
mapping of post translational modifications, such as protein phosphorylation, which has 
emerged as a new sub-discipline in the field of proteomics 114-116. Reversible protein 
phosphorylation is a key regulatory mechanism involved in almost all cellular activities 69, 117, 
118 and thousands of phosphorylation sites have been mapped by combining mass 
spectrometry with dedicated enrichment strategies 72, 73, 119-121. Despite this progress, however, 
the complete characterization of all phosphorylation sites is still challenging. 
High throughput protein identification is based on the mapping of the best matches 
between experimental tandem mass spectrometry (MS/MS) spectra and theoretical 
fragmentation patterns calculated from known protein sequences 122, 123. Even though intact 
proteins have been successfully analyzed by MS/MS 124, 125, this technique is far more 
sensitive when applied to peptides in the range of 5 to 25 amino acids. Therefore, proteins are 
digested by proteases prior to MS/MS analysis, and trypsin (cleaving at the C-termini of 
lysine and arginine) is generally the enzyme of choice due to its high cleavage specificity 111. 
 Detection and fragmentation efficiencies of peptides depend strongly on their size and 
sequence 112. This bias of MS/MS towards a subset of peptides is not a serious obstacle for 
confident protein identification since only a few good peptide-spectrum-matches (PSMs) are 
sufficient to accomplish this task. However, complete sequence coverage of proteins is 
mandatory for a comprehensive mapping of post-translational modifications. Since this goal 
can rarely be achieved using only one enzyme, analysis of samples after proteolysis with 
different enzymes is a common strategy to increase protein sequence coverage 126, 127. In 
particular, highly specific proteases, such as Glu-C (cleaving at the C-terminus of glutamic 
acid) and Lys-C (cleaving at the C-terminus of lysine), have been used in phosphoproteome 
studies 128. However, Lys-C frequently produces very large peptides, which are often less 
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suitable for collision induced dissociation (CID) MS/MS analysis, and the cleavage specificity 
of Lys-C partially overlaps with that of trypsin. Similarly, Glu-C digestion generates mostly 
large peptides and a dramatic decrease in the number of detected peptides has been observed 
when this enzyme was applied to complex samples 128. 
 As an alternative to specific enzymes, low-specificity proteases such as elastase, pepsin, 
thermolysin and proteinase K have also been applied to increase the sequence coverage of 
selected proteins 127, 129-131. Amongst these enzymes, elastase has attracted particular attention 
since it generates mainly medium sized peptides in the mass range between 500 Da and 1500 
Da 129. The disadvantage of low-specificity proteases, however, is a strong increase in search 
time and a strong decrease in search specificity. Whereas spectra of tryptic peptides only need 
to be matched against all tryptic database peptides in the measured mass window, the search 
space increases more than 100 fold if no enzyme is specified 111. Thus, a search without 
enzyme specificity corresponds to a search against a much larger database resulting in 
decreased detection sensitivity 132 and higher false discovery rate (FDR). Therefore, low-
specificity enzymes have mostly been used to increase the sequence coverage of well defined 
samples of modest complexity 127, 129-131. Even though low-specificity proteases have not yet 
been used successfully in large-scale phosphoproteome studies, their application may profit 
strongly from the recent development of highly accurate and sensitive Orbitrap mass 
spectrometers 31. As a result of mass accuracies in the low ppm range 133, the search 
specificity increases strongly since only peptides in a very narrow mass window have to be 
matched against the corresponding MS/MS spectra.  
The present study was aimed at evaluating to what degree the disadvantages of low-
specificity enzymes may be compensated for by the high mass accuracy of the Orbitrap. 
Specifically, we have analyzed the performance of the low-specificity protease elastase, in 
comparison with trypsin, in a large-scale phosphoproteome analysis of mitotic spindle 
preparations from human cells 84. Mitotic spindles are essential for accurate chromosome 
segregation during cell division 83, 134-137. Many spindle proteins are regulated by kinases and 
phosphatases and, therefore, a comprehensive mapping of phosphorylation sites in these 
proteins would clearly be important 138, 139. The results of our present analysis demonstrate 
that elastase is highly complementary to trypsin and efficient in increasing the coverage of 
phosphorylation sites. With an optimized MS mass error window, an improved database 
 46 
 
search strategy, and the introduction of a novel elastase cleavage specificity factor, we have 
successfully limited the FDR in a large scale dataset. (All optimization of data analysis was 
carried out in collaboration with Dr. Rainer Malik, MPIB). 
3.2.2 Experimental outline 
Elastase was compared to trypsin for the identification of phosphorylation sites from a 
complex mixture of proteins associated with the human mitotic spindle 83, 84. To this end, 
purified spindles were separated on two 1D gels and gel slices digested with elastase or 
trypsin, respectively. Subsequently, TiO2 enriched phosphorylated peptides and the flow-
through fractions from the TiO2 columns (un-phosphorylated peptides) were analyzed by LC-
MS/MS on an Orbitrap mass spectrometer.  
3.2.3 Adjustment of the Elastase Concentration 
To adjust the elastase concentration for proteolysis, we digested gel-separated samples 
of Bovine Serum Albumin (BSA) at elastase concentrations of 3.75 ng/µl, 7.5 ng/µl, 15 ng/µl, 
30 ng/µl, and 60ng/µl for 16-hours. We found that both the sequence coverage and the 
background of peptides derived from elastase auto-proteolysis increased with increasing 
enzyme concentration (data not shown). A concentration of 15 ng/µl was chosen as the best 
trade-off between sequence coverage and elastase auto-proteolysis peaks and hence was used 
for all subsequent experiments.  
3.2.4 MS Mass Accuracy 
The high mass accuracy of the LTQ-Orbitrap was expected to be crucial to partially 
compensate for the lower specificity of elastase cleavage. To evaluate the dependencies of the 
number of true positive identifications and false discovery rates (FDRs) from the employed 
MS mass error settings, trypsin and elastase derived datasets (18 gel slices, each) were first 
searched with MASCOT against SwissProt human (merged with a reversed decoy database) 
at a mass error of 7 ppm. Results were then combined using MaxQuant and subsequently 
filtered at mass accuracy stringencies ranging from 1 ppm to 7 ppm. The FDR was initially 
reduced by applying a MASCOT cut-off score of 20. Next, we calculated (table 2) and plotted 
(figure 22) the ratios between the hits in the forward database and the FDR to identify the best 
compromise between search sensitivity (number of identifications) and accuracy (low FDR). 
From figure 22, it becomes obvious that the ratios between the number of identifications and 
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the FDR peak at a mass accuracy setting of 2 ppm, so this value was employed for all 
subsequent analyses.  
 
Table 2. Numbers of phosphorylated peptide identifications in the forward database 
and FDRs for different mass accuracy settings. Search results of LC-MS/MS spectra 
with MASCOT identification scores >20 of trypsin and elastase digested samples were 
combined.  
 
mass error 
window 
peptides FDR no. of reverse 
hits 
no. of 
forward 
hits 
no. of forward 
hits/FDR*100 
±1ppm 1.0% 18 3633 3633.0  
±2ppm 1.0% 20 4171 4171.0  
±3ppm 1.1% 23 4281 3891.8 
±4ppm 1.2% 27 4313 3594.2  
±5ppm 1.2% 27 4327 3605.8  
±6ppm 1.3% 28 4335 3334.6  
±7ppm 1.3% 28 4345 3342.3  
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Figure 22. Ratios between the numbers of  identifications  in the forward database and the FDRs for 
different mass  accuracy  settings.  Search  results  of  LC‐MS/MS  spectra with MASCOT  identification 
scores >20 of trypsin and elastase digested samples were combined. 
 
3.2.5 Elastase cleavage specificity 
It has been reported previously that elastase cleaves predominantly C-terminal of the 
amino acids Gly, Val, Leu, Ala, and Ile, and to a lesser extent after Phe, Pro, Glu, and Arg 131, 
140. These results, however, were derived from only one substrate protein (elastin), and the 
conditions used for digestion did not exactly match the ones employed in our study. 
Therefore, we determined the cleavage frequencies of elastase C-terminal to the 20 common 
amino acids based on 931 high-scoring peptides (MASCOT score >25) from the elastase 1 
dataset (table 3). The cleavage probabilities were calculated by dividing the numbers of 
observed cleavages C-terminal to each the amino acid by the number of the occurrences of the 
same amino acid in the sequences of the detected peptides. Cleavage probabilities above 10% 
were observed (in decreasing order) for Ala, Val, Ile, Thr, Ser, Leu, and Met, which is only in 
partial agreement with the studies cited above. This discrepancy, however, may be explained 
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by the different source of enzyme, different digestion conditions (i.e. in-gel versus in-
solution), and the much broader range of substrates in our analysis. 
 
Table 3. Cleavage Frequencies of Elastase at the C- Termini of 20 Standard Amino 
Acidsa 
amino acid cleavages observed total number of 
residues  
cleavage probability 
A 357 820 43.5% 
V 314 861 36.5% 
I 241 694 34.7% 
T 190 627 30.3% 
S 197 919 21.4% 
L 267 1367 19.5% 
M 31 198 15.7% 
H 14 154 9.1% 
G 85 969 8.8% 
N 28 435 6.4% 
C 2 33 6.1% 
R 22 378 5.8% 
Q 33 599 5.5% 
Y 10 204 4.9% 
K 13 466 2.8% 
F 7 521 1.3% 
D 10 1056 0.9% 
E 9 1427 0.6% 
P 3 783 0.4% 
W 0 50 0% 
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a From dataset elastase 1, SwissProt human search, 931 elastase derived peptides from TiO2 
elution and TiO2 flow-through samples. FDR 1%, MS mass accuracy ±2 ppm, MS/MS mass 
accuracy ±0.3 Da. 
 
3.2.6 Elastase cleavage scores  
                      *Established in collaboration with Dr. Rainer Malik (MPIB) 
Even though proteolysis by elastase is much less specific than proteolysis by trypsin, the 
determined cleavage probabilities may be used to increase the specificity of peptide 
identifications in protein databases. Unlike for trypsin, however, the strict cleavage rules 
applied in MASCOT searches and the upper limit of nine missed cleavage sites are not 
appropriate for elastase, since cleavages probabilities are more broadly distributed over the 20 
amino acids (table 3). Therefore, we decided to search the spectra of elastase derived peptides 
with the “no enzyme” setting and then filter the identified peptides in a second step, using the 
determined cleavage probabilities to reduce the number of false positive identifications. To 
this end, we defined external cleavage scores for identified peptides in the forward and decoy 
databases (at an FDR of 5%). These scores were calculated as the product of the elastase 
cleavage probability of the amino acid at the C-terminus of each peptide multiplied by the 
cleavage probability of the C-terminal amino acid of the preceding peptide (the amino acid N-
terminal to the peptide’s N-terminus): 
).(.*).(._ CprobcleavNprobcleavScoreExternal =  
where cleav.prob(N) represents the cleavage probability of the C-terminal amino acid of the 
preceding peptide (the amino acid N-terminal to the peptide’s N-terminus) and cleav.prob(C) 
stands for the cleavage probability  of the amino acid at the peptide’s C-terminus (table 3).  
Next, we compared the medians of the external cleavage scores for the identifications in 
the forward versus the decoy database. As expected, the median external score among decoy 
database hits (0.0112) was considerably lower (7.6 fold) than that among forward database 
hits (0.0850), suggesting a substantial discriminative power of the external cleavage scores. 
Peptides composed of many amino acids with high elastase cleavage probabilities likely 
represent false positive identifications, since proteolytic cleavages within these peptides 
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would be expected. To evaluate if this expectation holds true, we calculated an internal 
cleavage score for each identified peptide in the forward and decoy databases (at a FDR of 
5%), defined as the product of 1 minus the cleavage probabilities of all but the C-terminal 
amino acid: 
∏ −= N NprobcleavScoreInternal
1
)).(.1(_  
where N represents all amino acids within the peptide sequence except the C-terminal amino 
acid and cleav.prob. stands for the elastase cleavage probabilities reported in table 3.  
As for the external cleavage score, we calculated the median internal scores for the hits 
in the decoy database (score: 0.145) and the forward database (0.191). Even though the 
discriminative power of the internal cleavage score (factor 1.3) is much lower than that of the 
external score (factor 7.6) we decided to use this factor as an additional means to increase 
search specificity. 
Instead of consecutively filtering the lists of forward and decoy hits using appropriate 
cutoff values of MASCOT scores, external scores, and internal scores, we calculated a 
combined score composed of these three factors by using Discriminant Function Analysis 
(DFA) 141, named as discriminant score (D-score).  
The centroids of the discriminant score distributions of hits in the forward and decoy 
databases were calculated as + 0.076 and -0.563, respectively, underlining the discriminative 
power of the D-score. Next, we determined that filtering the elastase dataset using a 
discriminant score cutoff of 25.1−=D  resulted in the desired FDR of 1%. Therefore, we 
used this cutoff value for all subsequent data analyses.  
 
3.2.7 Comparison of phosphorylation site identification using trypsin 
and elastase 
       After having optimized the database search strategy for elastase derived peptides, we 
aimed to evaluate to what degree digestion by elastase could complement digestion by trypsin 
for phosphorylation site identification. In experiment 1, equal amounts of spindle proteins 
were processed in parallel with trypsin and elastase, respectively. MS spectra were searched 
against SwissProt human (including a reversed decoy database) using MASCOT. Whereas 
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trypsin derived samples were searched using trypsin specificity settings, the “no enzyme” 
option was used for elastase derived spectra. Next, the FDR was reduced by filtering of the 
peptide lists with the optimized ± 2 ppm mass accuracy criterion, and, for the elastase dataset, 
the discriminant score. Furthermore, in order to ensure the reliability of phosphorylation site 
identifications and to further decrease the FDR, a cutoff of the localization probability score 
(as provided by MaxQuant) of 75% was set, corresponding to the class of phosphorylation 
sites with highest confidence in localization 64. This resulted in the identification of 703 
phosphorylation sites using trypsin versus 185 phosphorylation sites from the elastase sample 
(figure 23). Although, the number of unique phosphorylation sites found with elastase was 
much lower than that from the tryptic sample, there was an overlap of only 4.2%, suggesting 
that trypsin and elastase are highly complementary in large scale phosphoproteome studies.  
 
 
 
 
 
 
 
 
Figure  23. Detected  Phosphorylation  sites  using  trypsin  or  elastase  for  database  searches  against 
SwissProt human.  
        To evaluate whether the lower number of detected phosphorylation sites using elastase 
digestion was related to the larger search space (“no enzyme” search setting), we also 
searched the trypsin derived dataset against SwissProt human using the “no enzyme” option. 
Compared to the more specific search, the number of identified peptides decreased greatly 
(40% reduction, data not shown), suggesting that the larger search space is indeed a major 
factor in explaining the lower number of identified peptides using elastase. Therefore, we next 
aimed at decreasing the search space for the elastase datasets without compromising the 
confidence of peptide identifications. 
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3.2.8 “Custom database” search strategy 
It has been reported that database size significantly affects the sensitivity of database 
search algorithms 142. Since large databases include more protein/peptide sequences, the 
chance of random assignments also increases. On the other hand, a database should be 
sufficiently large to contain all detectable proteins present in the sample since spectra may be 
matched to the false second-best-hit if the correct hit is not present in the database.  
        Here we introduce a two-step search strategy to increase the search sensitivity while 
maintaining high stringency for phosphorylation site identification. In the first step, the MS 
spectra of trypsin and elastase digested TiO2 elution and flow-through samples were searched 
against SwissProt human (including the decoy database) with a relaxed protein/peptide FDR 
< 5%. After removing the decoy hits, a “custom database” containing 1030 identified proteins 
was built and concatenated with a decoy version of this novel database. To ensure that the 
“custom database” indeed covers the detectable proteins in our samples, the numbers of 
unassigned spectra in four representative elastase LC-MS/MS runs against SwissProt human, 
and the “custom database”, were compared. The number of unassigned spectra decreased 
slightly (by 86 unassigned spectra for the four LC-MS/MS runs) for the “custom database” 
search strategy whereas the opposite trend would be expected if the custom database would 
not largely cover all detectable proteins in the sample. 
The elastase and trypsin datasets were then searched against this “custom database” 
using identical filtering criteria as for the SwissProt search. Employing this new minimal 
database strategy, the number of identified phosphorylation sites using elastase increased by 
85% to 343 sites (figure 24), while the number of phosphorylation sites found with trypsin 
increased only moderately by 13% (795 phosphorylation sites, figure 24). Importantly, the 
overlap between the datasets is still low (6.8%), presumably reflecting high complementarity 
of the elastase and trypsin cleavage specificities.  
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Figure 24. Detected Phosphorylation sites using trypsin or elastase  for database searches against a 
“custom database”. 
3.2.9 Complementary phosphorylated peptide coverages using trypsin 
and elastase 
          *Established in collaboration with Dr. Rainer Malik (MPIB) 
To rationalize the highly complementary coverage of phosphorylated peptides detected 
by trypsin and elastase we analyzed whether the theoretical size of tryptic peptides covering 
elastase derived phosphorylation sites would be outside the optimal sensitivity range for our 
experimental strategy. Figure 25 shows the length-distributions of phosphorylated peptides 
observed after tryptic digestions, elastase digestions, and the theoretical tryptic peptides 
covering elastase derived phosphorylation sites. Interestingly, the size distribution of the 
theoretical tryptic peptides (mean: 18.32 amino acids, standard deviation: 13.64 amino acids) 
is much broader than the observed distributions of experimentally determined tryptic (mean 
11.24 amino acids, standard deviation: 2.80 amino acids) and elastase (mean 11.56 amino 
acids, standard deviation: 2.52 amino acids) derived phosphorylated peptides (figure 25B). 
Importantly, many of the tryptic peptides phosphopeptides would not have been detected 
using trypsin since the resulting peptide sizes are not optimal. The most pronounced example 
regarding this observation is the phosphorylation site S486 (phosphorylated peptide 
GGS(ph)FGAYGAQEEAQCPT) of the major centromere autoantigen B (CENPB_HUMAN) 
which was detected after elastase digestion. The corresponding tryptic peptide would have a 
molecular weight of 17 kDa (153 AA), thus it would be very unlikely to observe such a 
peptide in a large-scale experiment after trypsin digestion. 
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Figure  25.  (A)  Size  distribution  of  theoretical  tryptic  peptides  covering  elastase  derived 
phosphorylation  sites.  (B)  Size  distributions  in  the  range  between  1  and  25  amino  acids  of 
experimentally  identified  tryptic phosphorylated peptides  (green), elastase derived phosphorylated 
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peptides  (red),  and  theoretical  tryptic  peptides  covering  elastase  derived  phosphorylation  sites 
(blue). 
3.2.10  Testing for undersampling effects 
Finally, we aimed to confirm that the observed low overlap between the trypsin and 
elastase datasets was indeed a consequence of enzyme complementarity and not a sole 
undersampling effect due to high sample complexity 143. To this end, in a second experiment, 
we analyzed the elastase and trypsin fractions twice (details see materials and methods) and 
compared the observed overlaps of identified phosphorylation sites from the four datasets 
(trypsin 2a, trypsin 2b, elastase 2a, and elastase 2b). Figures 26A and 26B  show that the 
overlaps from the repeated trypsin and elastase analyses are about 50% each, whilst the 
overlap between trypsin and elastase derived datasets is clearly lower (8.1%, figure 26C). 
Therefore, it can be concluded that the observed low overlap between the phosphorylation 
sites identified using either trypsin and elastase indeed reflects the complementary cleavage 
properties of these enzymes. 
Combining the results of both experiments, we have identified 1068 phosphorylation 
sites from tryptic peptides and 467 phosphorylation sites using elastase. The overlap of those 
two datasets is only 9.9% (139 sites), demonstrating the value of using elastase in addition to 
trypsin to increase phosphorylation site coverage in complex samples.  
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Figure  26. Detected  phosphorylation  sites  for  repeated  experiments  using  trypsin  or  elastase  for 
database searches against the “custom database”.  
 
 
 5 
4 Discussion 
        The Plk1 dependent spindle phosphoproteome project demonstrates the use of mass 
spectrometry based proteomics techniques to generate insight into important biological 
signaling networks. Using rigorous filtering criteria, we identified in total 4420 unique 
phosphorylation sites from inhibitor and shRNA experiments (with a false-positive rate 
(FDR) of 0.89 % (see Results)). Of these, 1943 phosphorylation sites (more than 40%) have 
not been annotated in Uniprot (version 15.11), and to the best of our knowledge, have not 
been previously reported in the literature. The large number of confidently identified 
phosphorylation sites demonstrates the high efficiency of the employed proteomics strategy. 
Especially, enrichment of phosphorylated peptides by titanium affinity beads combined with 
highly sensitive LC-MS/MS techniques can be considered as key techniques to reproducibly 
improve phosphoproteome coverage.  
        The phosphoproteomes identified with high confidence from inhibitor and shRNA 
approaches comprise similar numbers of phosphorylation sites, 3526 and 3212, respectively. 
However, from 702 down-regulated phosphorylation sites, 527 were observed after TAL 
treatment and only 268 sites after Plk1 depletion by shRNA. Chemical inhibition of Plk1 
resulted in a larger number of identified down-regulated phosphorylation sites and stronger 
down-regulation at individual sites than Plk1 depletion, likely reflecting both incomplete 
depletion of Plk1 in the shRNA cell line and the potent inhibition of Plk1 by TAL 86. 
Nevertheless, although the number of down-regulated sites identified upon Plk1 depletion was 
lower, more than two thirds of these sites did not overlap with those down-regulated upon 
TAL treatment (figure 16B), supporting the use of complementary strategies to interfere with 
Plk1 for better coverage of significantly regulated phosphorylation site identification.  
        There were 304 human proteins identified with Plk1 dependent phosphorylation sites. 
35% of these proteins are related to mitotic spindle function 83, 84, demonstrating a substantial 
enrichment for spindle components in our samples. 
        Among the spindle proteins containing down-regulated phosphorylated sites, those 
associated with the centromere or KT structure were overrepresented, consistent with an 
important role for Plk1 in KT function (figure 19). This included the centromeric protein 
PBIP1, the protein kinase Bub1 and the subunit of the chromosomal passenger complex, 
INCENP, all known to contribute to KT localization of Plk1 during mitosis 144-146. 
8 
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Interestingly, members of the nuclear pore complex (NUPs), previously shown to associate 
with KTs at the onset of mitosis 147, also showed down-regulated sites after Plk1 inhibition 
(Figure 19). Furthermore, APC subunits, other mitotic kinases, tubulin subunits and proteins 
functioning in chromosome structure, appeared also to be regulated by Plk1. Our data set 
contained known Plk1 substrates, such as Cdc27, INCENP, Kif20A, and TOPOIIA 13, 148, 
which validate our experimental strategy.  
        The analysis of the sequence motifs of confirmed Plk1 phosphorylation sites (see 
Results) revealed that, in addition to the previously reported D/E-X-S/T-Φ motif, many Plk1 
phosphorylation sites conformed to slightly different sequence features, i.e. a N at the -2 
position was observed frequently. Detailed alignment analyses and additional peptide spotting 
experiments suggested the broadened motif L(Φ)-E/N/D(Q)-X-S/T-(Φ) as a Plk1 substrate 
consensus, thus  refining our current knowledge on Plk1 activity.  
        Interestingly, we found that many Plk1 substrates showed reduced association with the 
spindle, when Plk1 levels were reduced by shRNA or when Plk1 activity was inhibited by 
TAL. This observation suggests that phosphorylation by Plk1 is required for the correct 
localization of many spindle components, thus providing important insight into the functions 
of Plk1 phosphorylation.  
        In summary, in the first part of this thesis we have identified 360 unique Plk1-dependent 
phosphorylation sites on mitotic spindle proteins, including novel substrates, illustrating the 
complexity of the Plk1-dependent signaling network. Over 100 sites were validated by in 
vitro peptide arrays. Importantly, in line with the distinct localization of Plk1 at the 
centrosomes, spindle and KTs in early mitosis, and its relevant roles in centrosome 
maturation, spindle assembly and KT-MT stability, the isolation of purified spindles allowed 
us to enrich for relevant Plk1 targets and phosphorylation sites on the mitotic spindle. Our 
comprehensive study of phosphoregulation by Plk1 vastly extends the inventories of direct 
Plk1 substrates, Plk1-dependent phosphorylation sites on the mitotic spindle apparatus, and 
downstream effectors of Plk1 in mammalian cells. These data should thus serve as a valuable 
resource for future research in the field. The strategies developed here for the analysis of the 
Plk1-dependent proteome and phosphoproteome on the mitotic spindle can in principle be 
applied to other protein kinases, provided that effective shRNA duplexes and/or specific 
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inhibitors are available. These strategies thus respond to a growing contemporary need for 
assigning experimental phosphoproteome data sets to specific individual kinases. 
The results of the Plk1 project demonstrate that thousands of phosphorylation sites can 
be identified by mass-spectrometry based phosphoproteome analysis in a robust fashion, thus 
allowing for comparative SILAC based analyses of considerable biological interest. However, 
many important phosphorylation sites may still remain undetected due to bias of the 
employed enrichment strategy towards certain sequence related features. Especially, the 
specificity of trypsin, the protease employed for in-gel digestion of gel-separated proteins, 
may favor the detection of phosphorylation sites within tryptic peptides of optimal sizes and 
physiochemical properties. The detection and sequencing sensitivity of most mass 
spectrometers is optimal for peptides of 6-20 amino acid lengths so longer or shorter peptides 
may frequently remain undetected. Trypsin is almost exclusively used in proteomics 
experiments since it works highly efficient and because its strict cleavage specificity strongly 
increases the database search efficiency (only tryptic peptides have to be considered).  
However, complete sequence coverage of proteins can unfortunately not be achieved 
employing a single protease. Therefore, in the second part of this thesis we decided to 
evaluate the use of alternative enzymes to complement trypsin based proteome analyses. Low 
specific enzymes should be well suited to reach higher sequence coverage since overlapping 
peptides are frequently generated. In particular, elastase generates mainly medium sized 
peptides in the mass range between 500 Da and 1500 Da and has the potential advantage of 
being a good complement to trypsin due to its cleavage low-specificity. To evaluate elastase 
for phosphoproteome studies, equal amounts of spindle proteins were processed in parallel 
with trypsin and elastase for phosphorylation sites identification. Obtained MS spectra were 
searched against the same database whereas trypsin search was under trypsin specificity 
setting and elastase search was under “no enzyme” setting. Using this strategy, we identified 
703 phosphorylation sites identified using trypsin versus 185 phosphorylation sites using 
elastase (see figure 23). The reduced number of identified phosphorylation sites after elastase 
digestion compared to trypsin, can be explained by several factors: First, trypsin derived 
peptides are especially suitable for MS/MS based identification due to protonated amino acids 
(Arg, Lys) at their C-termini, often resulting in pronounced y-ion series, and the low 
frequency of internal Arg and Lys residues, known to adversely affect fragmentation patterns. 
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Second, the detection sensitivity after elastase digestion might be hampered by the possible 
spread of the signal to multiple overlapping peptides. Third, as mentioned in the Results 
section, the vastly increased search space as a result of the “no enzyme” setting may adversely 
affect the sensitivity of the MASCOT search engine. As shown in the Results section, the 
database size has indeed a strong influence on the number of identified phosphorylation sites 
when searches without enzyme specificity are conducted. 
        The much higher increase of phosphorylation site identifications for elastase compared 
to trypsin employing the “custom database” search strategy can be explained by the much 
larger effect on the search space when using the “no enzyme” setting. Whilst the sensitivity of 
the MASCOT search algorithm was sufficient to detect a high proportion of PSMs using 
tryptic search specificity, this sensitivity suffered apparently strongly from the larger search 
space for the elastase data. Thus, the result for the elastase dataset profits strongly from the 
more specific search against the “custom database” whereas most correct PSMs of the tryptic 
dataset were already detected during the SwissProt search. Importantly, the estimated FDRs 
for these datasets are still low (0.3% for trypsin, 1.2% for elastase), even though it must be 
noted that these numbers cannot be directly compared to the SwissProt FDRs as FDRs 
generally depend on search space, even for identical MS/MS spectra. Importantly, however, 
the search space of the elastase search against the custom database (1030 sequences) is still 
about seven times larger compared to the trypsin dataset search against SwissProt human 
(14475 sequences), since the “no enzyme” setting for the elastase search increases the search 
space by approximately 100 times 111. Thus, we can conclude that the proposed search 
strategy is statistically sound, provided that the “custom database” represents a good coverage 
of the detectable proteins in the samples, as shown in the Results section.  
        We have demonstrated that the employed search strategy provides an efficient means to 
increase the number of detectable peptides using low-specificity enzymes. It is conceptually 
similar to the second-pass search strategy 153, in which highly specific search criteria are used 
for the first search, and the coverage of  peptides for the identified proteins is increased in the 
second pass search using more relaxed search criteria (i.e. more variable modifications, wider 
mass error windows). Even though in our search strategy the “second-pass search” is run with 
identical search criteria, we also take advantage of the strongly reduced search space to 
identify more phosphorylation sites. 
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        By employing the two-step database search method, the overlap of protein 
phosphorylation site identification between trypsin and elastase was still low (6.8%), which 
reflects high complementarity of the elastase and trypsin cleavage specificities. This point 
was further confirmed by the length-distributions of phosphorylated peptides observed after 
tryptic and elastase digestions (figure 25). By comparing the length-distributions of tryptic, 
elastase and the theoretical tryptic peptides covering elastase derived phosphorylation sites, it 
can be concluded that many of the phosphorylation sites discovered after elastase digestion 
would be either too small or too big to be detected with high sensitivity after tryptic digestion. 
In addition to peptide lengths, other sequence related physicochemical properties 112 may 
further contribute to the low overlap between trypsin and elastase derived phosphorylation 
sites.  
        In summary, in the second part of this thesis we have investigated the use of elastase in 
comparison to trypsin for the phosphoproteome analysis of samples enriched for human 
mitotic spindle proteins. We found that trypsin was clearly more efficient than elastase in 
generating detectable peptides for phosphorylation site identification. However, by 
determining the cleavage preferences of elastase and optimizing the database search strategy, 
we show that it is possible to robustly improve phosphorylation site identification from low 
specificity protease digests. 
        Importantly, the cleavage specificities of trypsin and elastase were found to be highly 
complementary, providing about 30% additional phosphorylation sites using elastase. 
Therefore, as already established for studies focused on specific proteins, we propose to use 
parallel digestions with various specific and unspecific enzymes to approach towards 
complete sequence coverage in large-scale proteomics studies. To this end, the presented 
improved search strategy may also be applied to other low-specificity proteases, such as 
pepsin, proteinase K, or thermolysin.  
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5 Material and Methods 
5.1 Quantitative identification of Polo-like kinase 1 (Plk1) specific 
phosphorylation sites on human mitotic spindle protein 
5.1.1 Materials 
Glycine, trifluoroacetic acid (25%), acetic acid, formic acid (98-100%), acetonitrile, 
methanol and ammonia solution (25%) were obtained from Merck. 2-Propanol was from Carl 
Roth. Lactic acid (~90%) was ordered from Fluka. NuPAGE Bis-Tris gels (1.0mm thick, 12 
lanes per gel) and NuPAGE lithium dodecyl sulfate (LDS, 4 ×) sample buffer were from 
Invitrogen. DL-Dithiothreitol (DTT, >99%) and iodoacetamide were obtained from Sigma. 
Proteomics grade trypsin was purchased from Roche (Mannheim, Germany). Titansphere (10 
µm) was from GL Sciences Inc. (Japan) and GELoader tips were purchased from Eppendorf. 
The 3M Empore C8 and C18 disks were obtained from 3M Bioanalytical Technologies (St. 
Paul, MN). 
5.1.2 SILAC media 
DMEM high glucose medium deficient in amino acids arginine and lysine was 
supplemented with 5% dialysed FCS, penicillin-streptomycin (100 U/mL and 100 µg/mL, 
respectively), and either unlabelled Arginine.HCl and Lysine.HCl (SILAC light) or L-
arginine-U-13C6-15N4.HCl and L-lysine-U-13C6-15N2.HCl (Cambridge Isotope 
Laboratories) (SILAC heavy) at concentrations of 42 µg/mL (Arginine) and 72 µg/mL 
(Lysine).  
5.1.3 Cell culture and spindle isolation 
Cells were grown at 37 °C in a humidified incubator with a 5 % CO2 atmosphere. Cells 
were adapted to the appropriate SILAC medium for at least 6 passages to achieve complete 
incorporation of the isotopically labeled amino acids. For large-scale mitotic spindle isolation, 
each population of HeLa S3 labeled cells was propagated to 5 culture triple-flasks, with a total 
surface of 500 cm2. Cells were first pre-synchronized with thymidine (2 mM) for 20 h, then 
washed twice with PBS, and released from the thymidine block into TAL or Monastrol-
containing medium (1µM or 150 µM, respectively), or by induction with 1 µg/ml tetracycline 
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for 36 or 48 h (Plk1 or Eg5 shRNA respectively), in case of the inducible cell lines. Taxol-
stabilized mitotic spindles (including kinetochores and centrosomes) were isolated essentially 
as described previously 93 Briefly, taxol (5 µg/mL) was added to pre-lysis and lysis buffers to 
stabilize spindles. Cells were then treated with DNAses and latrunculin B to partially remove 
chromosomes and to depolymerize the actin cytoskeleton, respectively. Intermediate 
filaments were subsequently depolymerized in low-ionic-strength buffer and the mitotic 
spindles collected by centrifugation. The purity of isolated spindles was evaluated by DIC 
light microscopy. (performed by Anna Santamaria) 
5.1.4 In vitro kinase assays 
       Plk1 and Aurora A activity was assayed in kinase buffer (50mM Tris-HCl pH7.5, 10 mM 
MgCl2, 1 mM DTT, 100 uM NaF, 10uM Sodium Vanadate) and (20 mM Hepes pH 7.4, 150 
mM KCl, 5 mM MnCl2, 5 mM NaF and 1mM DTT), respectively, using His-tagged Plk1 and 
Aurora A, respectively. Casein and MBP were used as model substrates. Reactions were 
mixed, incubated for 30 min at 30 °C and stopped by the addition of Laemmli sample buffer. 
Proteins were resolved by SDS-PAGE and gels were dried before being visualized by 
autoradiography. (performed by Sabine Elowe) 
5.1.5  Gel Electrophoresis and In-Gel Digestion 
Enriched spindle proteins were separated by SDS-PAGE and in-gel 154 digested with 
trypsin. In each experiment, about 400 µg spindle proteins were loaded to one NuPAGE Bis-
Tris gel and run for 50 min using a 200-V/100-mA program. Gels were stained with a 1:1 
mixture of 0.2% Coomassie blue in MeOH and 20% acidic acid for 40 min, and destained 
using a mixture of 30% MeOH and 10% acetic acid for 15 min, 10% acetic acid for 1 hour, 
and 2% acetic acid over night at 4°C. Gels were cut into 18 slices each according to the 
separation of spindle proteins. After reduction and alkylation, proteins were digested by 15 
ng/µl trypsin for 16h. Digested peptides were extracted with 30% AcN/5% formic acid and 
dried. 
5.1.6 Enrichment of Phosphorylated Peptides and Desalting 
Phosphorylated peptides were selectively enriched by titanium dioxide beads with lactic 
acid as a modifier 74. A piece of C8 material was plugged at the constricted end of GELoader 
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tip and about 3 mg titanium dioxide beads was transferred to each of the micro-columns. The 
micro-columns were washed with 40 µl of 0.3 µg/µl lactic acid in a mixture of 80% ACN and 
0.2% TFA. Digested peptides were re-dissolved in 0.3 µg/µl lactic acid in a mixture of 80% 
ACN and 2% TFA, and applied to micro-columns with slow flow rate allowing 
phosphorylated peptides to bind to the titanium dioxide beads. The micro-columns were 
subsequently washed with 40 µl of 0.3 µg/µl lactic acid in a mixture of 80 % ACN and 0.2% 
TFA and 40 µl of a mixture of 80% ACN and 0.2% TFA. Phosphorylated peptides were 
eluted with 40 µl of 0.6% NH4OH and 40 µl of a mixture of 80% ACN and 0.2% TFA. The 
eluates were dried and re-dissolved with 0.5% formic acid for LC-MS/MS analysis. 
The flow-through fractions were desalted with C18 reversed-phase material prior to LC-
MS/MS for protein expression level measurement. Briefly, a piece of C18 material was 
plugged into a GELoader tip, washed with 20 µl of 2-propanol and 20 µl of 5% formic acid. 
The dried flow-through fractions were re-dissolved with 20 µl 5% formic acid and applied to 
the C18 micro-columns. The columns were then washed with 20 µl of 5% formic acid and 
subsequently peptides were eluted with 2×20 µl of 50% methnol/2% formic acid. The eluates 
were dried and re-dissolved with 0.5% formic acid for LC-MS/MS. 
5.1.7 Nano LC-MS/MS 
The nano LC-MS/MS analysis was performed with a nanoACQUITY ultra performance 
liquid chromatography (UPLC) system (Waters, UK) connected to a hybrid linear ion 
trap/Orbitrap tandem mass spectrometer (Thermo Electron, Germany). Dissolved peptides 
were loaded at 500 nl/min into a pulled and fused silica capillary with an inner diameter of 75 
µm and a tip of 8 µm (New Objective, USA) packed to a length of 12 cm with reversed-phase 
ReproSil-Pur C18-AQ 3 µm resin (Maisch, Germany), and eluted at 200 nl/min by a stepwise 
180 min gradient of 0-100% between buffer A (0.2% formic acid in water) and buffer B 
(0.2% formic acid in acetonitrile).  
The LTQ mass spectrometer was operated in a data-dependent MS/MS mode. Survey 
full scan MS spectra (from m/z 300 to 2000) were acquired in the FT-Orbitrap with a 
resolution of 60 000 at m/z 400. A maximum of five peptides were sequentially isolated for 
fragmentation in the linear ion trap using collision induced dissociation (CID). The lock mass 
option was enabled to improve mass accuracy as described 133. All spectra were acquired with 
Xcalibur software. 
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5.1.8 Database searching and Data Filtering 
MS spectral were searched via MASCOT 123 (version 2.2.0, Matrix Science, London, 
U.K.) search engine against a composite Human International Protein Index sequence 
database (IPI, Version 3.48) which was concatenated with its reversed complement 155. Peak 
lists were generated using MaxQuant 156 (version 1.0.12.5), which also performs SILAC 
quantitation, FDR determination, peptide/protein grouping, phosphorylation sites localization 
probability scoring, and data filtration based on MASCOT search results. Maximum allowed 
monoisotopic precursor mass error was set to ±7 ppm, whereas an accuracy of ± 0.5 Da was 
used for MS/MS peaks. Enzyme specificity was set to trypsin and allowing cleavages N-
terminally to proline. Carbamidomethylation was set as fixed modification. Oxidation, protein 
N-terminal acetylation, Arg10, Lys8 and phosphorylation (STY) were considered as variable 
modifications. A maximum of three labeled amino acids, two missed tryptic cleavages and a 
minimum of six amino acids peptide length were allowed. A minimum of one unique peptide 
was required for protein identification. Estimated peptide/protein FDR were calculated as 
(number of hits in the reversed database / number of hits in the forward database) ×100% 157. 
Maximum 5% peptide FDR and 2% protein FDR were allowed for the first-step 
peptide/protein identification. MASCOT ion score ≥ 12 and phosphorylation sites localization 
probability ≥ 75% were used for data filtering. 
Automated quantitation was accomplished by MaxQuant software. The ratios of each 
ion pair with different SILAC labeling were normalized by corresponding protein expression 
levels which were quantitated only with unphophorylated peptides. Normalized 
phosphorylated peptide ratios show either an increase higher than 3/2-fold or a decrease lower 
than 2/3-fold in relative abundance under different SILAC labeling conditions, were 
considered as significantly down-regulated upon the depletion/inhibition of Plk1 95. 
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5.2 Phosphoproteome analysis of human mitotic spindle proteins by using 
low-specificity protease elastase 
5.2.1 Materials 
Elastase (from porcine pancreas) and proteomics grade trypsin were purchased from 
Roche (Mannheim, Germany), bovine serum albumin (>99%), DL-Dithiothreitol (DTT, 
>99%) and iodoacetamide from Sigma, NuPAGE Bis-Tris gels (1.0mm thick, 12 lanes per 
gel) and NuPAGE lithium dodecyl sulfate (LDS, 4 ×) sample buffer from Invitrogen, glycine, 
acetonitrile, trifluoroacetic acid (25%), acetic acid, methanol and ammonia solution (25%) 
from Merck, and lactic acid (~90%) from Fluka. Titanspheres (10 µm) were obtained from 
GL Sciences Inc. (Japan), GELoader tips from Eppendorf, and the 3M Empore C8 and C18 
disks from 3M Bioanalytical Technologies (St. Paul, MN).  
5.2.2 Cell Culture and Mitotic Spindle preparation 
Human mitotic spindles were isolated and enriched from 9×107 HeLa S3 cells as 
described in detail93, except that thymidine (5 mM for 21 hours) was used to synchronize cells 
in S-phase prior to the mitotic nocodazole block. In short, the synchronized mitotic cells were 
released after shake-off, and taxol was added to stabilize microtubules when most cells had 
reached metaphase. After lysis, DNAse was added to degrade chromosomes, whereas 
intermediated filaments were depolymerized in low ionic strength buffer. Finally, mitotic 
spindles were collected by centrifugation.  
5.2.3 Gel Electrophoresis and In-Gel Digestion 
In both experiments, isolated spindle proteins were split into two equal fractions, 
separated in parallel by 1D gel electrophoresis, and in-gel digested by trypsin or elastase, 
respectively. In experiment 1, for each gel 200 µg spindle proteins were suspended in 241 µl 
0.1 M glycine buffer and mixed with 80 µl 4 × LDS sample buffer and 16 µl  of 0.5 M DTT 
and heated for 10 min at 75°C. Spindle proteins were then separated on NuPAGE Bis-Tris 
gels for 50 min at 200-V/100mA. Gels were stained using a 1:1 mixture of 0.2% Coomassie 
blue in 50% MeOH and 20% acetic acid for 40 min, and destained using a mixture of 30% 
MeOH and 10% acetic acid for 15 min, 10% acetic acid for 1 hour, and 2% acetic acid over 
night at 4°C. Gels were cut into 18 slices each. Spindle proteins were then in-gel digested by 
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trypsin154 or elastase at concentrations of 15 ng/µl for 16 hours. After digestion, peptides were 
extracted and dried in a vacuum centrifuge. These samples were named trypsin 1 and elastase 
1. In experiment 2, 350 micrograms spindle proteins were applied to each gel. The samples 
were processed as in experiment 1, except that they were split prior to LC-MS analysis for a 
replicate analysis. These samples were named trypsin 2a, trypsin 2b, elastase 2a and elastase 
2b, respectively. 
5.2.4 Phosphorylated Peptide Enrichment and Sample Desalting 
Titanium dioxide beads were used to selectively enrich for phosphorylated peptides with 
lactic acid as a modifier74. About 3 mg of titanium dioxide beads were transferred to a 
GELoader tip (plugged at the constricted end by a small piece of C8 material) and washed 
with 40 µl of 0.3 µg/µl lactic acid in a mixture of 80% ACN and 0.2% TFA. Digested 
peptides were dissolved in 20 µl of 0.3 µg/µl lactic acid in a mixture of 80% ACN and 2% 
TFA, and applied to micro-columns allowing phosphorylated peptides to bind to the titanium 
dioxide phase. Micro-columns were then washed with 40 µl of 0.3 µg/µl lactic acid in a 
mixture of 80 % ACN and 0.2% TFA and 40 µl of a mixture of 80% ACN and 0.2% TFA. 
Finally, phosphorylated peptides were eluted slowly with 40 µl of 0.6% NH4OH and 
subsequently 40 µl of a mixture of 80% ACN and 0.2% TFA. Eluates and flow-through 
fractions were desalted with C18 reversed-phase material prior to LC-MS/MS analysis 
essentially as described 158. 
5.2.5 Nano LC-MS/MS 
The digested peptide mixtures were chromatographically separated with a 
nanoACQUITY ultra performance liquid chromatography (UPLC) system (Waters, UK) 
connected to a hybrid linear ion trap/Orbitrap tandem mass spectrometer (Thermo Electron, 
Germany). Peptides dissolved in 0.5% formic acid were loaded into a 14 cm pulled and fused 
silica capillary with an inner diameter of 75 µm and a tip of 8 µm (New Objective, USA) 
packed with reversed-phase ReproSil-Pur C18-AQ 3 µm resin (Maisch, Germany). Peptides 
were separated and eluted by a stepwise 180 min gradient of 0-100% between buffer A (0.2% 
formic acid in water) and buffer B (0.2% formic acid in acetonitrile). The mass spectrometer 
was operated in data-dependent MS/MS mode. Survey full scan MS spectra (from m/z 300 to 
2000) were acquired in the FT-Orbitrap with a resolution of 60 000 at m/z 400. A maximum 
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of five peptides were sequentially isolated for fragmentation in the linear ion trap using 
collision induced dissociation. The Orbitrap lock mass feature was applied to improve mass 
accuracy as described133. 
5.2.6 Data Processing and Analysis 
Peak lists were generated using MaxQuant (version 1.0.9.4)156, which also features 
spectra re-calibration based on high scoring peptides, phosphorylation site scoring within the 
sequences of identified phosphorylated peptides, false-discovery rate determination, and data 
filtering options after import of MASCOT result files. MASCOT (version 2.2.0, Matrix 
Science, London, U.K.)123 was used for peptide and protein identifications. For initial 
searches, the precursor mass tolerance was set to ±7 ppm, whereas an accuracy of ± 0.3 Da 
was used for MS/MS spectra. The MS mass error window was subsequently optimized during 
data analysis (see below). Carbamidomethylation was set as fixed modification, whereas 
oxidation, acetylation (protein N-terminal), and phosphorylation (STY) were considered as 
variable modifications. Trypsin/p was set as enzyme for tryptic peptides, and “no enzyme” 
was set for elastase derived peptides. Searches were performed against SwissProt human 
(release 54.4) and “custom databases” (see Results), which were concatenated with a reverse 
database155, 157. Peptide/protein false-discovery rates (FDR) were calculated as (number of hits 
in the reversed database / number of hits in the forward database) ×100% 157. 
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6 Abbreviations 
AC Alternating current 
ACN Acetonitrile 
APC/C Aanaphase-promoting complex/cyclosome 
AQUA Absolute quantitation 
BSA Bovine Serum Albumin 
CID collision induced dissociation 
CDITs Culture-derived isotope tags 
Cdk1 Cyclin-dependent kinase 1 
DC Direct current 
DHB 2,5-dihydroxy benzoic acid 
DFA Discriminant Function Analysis 
DTT DL-Dithiothreitol 
ESI Electrospray ionization 
FACS Flow cytometry 
FDR False discovery rate 
FTICR Fourier transform ion cyclotron resonance 
ICAT Isotope-coded affinity tages 
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ICPL Isotope-coded protein label 
IF Immunofluorescence 
IMAC Immobilized Metal Affinity Chromatography 
iTRAQ Isotope tags for relative and absolute quantification 
KTs Kinetochores 
LC Liquid chromatography 
LDS Lithium dodecyl sulfate 
LTQ Linear quadrupole ion trap 
m/z Mass to charge ratio 
MA Monastrol 
MALDI Matrix-assisted laser desorption/ionization 
MAPs Microtubule associated proteins 
MBP Myelin basic protein 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
MTs Microtubules 
NUPs Nuclear pore complex 
PBDs Polo-box domains 
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Plk1 Polo-like kinase 1 
PSMs Peptide-spectrum-matches 
RF Radio frequency 
SCX Strong Cation exchange chromatography 
SILAC Stable isotope labeling by amino acid in cell culture 
Tet Tetracycline 
TFA Trifluoroacetic acid 
TOF Time-of-flight 
UPLC Ultra performance liquid chromatography 
XIC Extracted ion current 
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8 Appendix 
Part II: Key features of identified down-regulated phosphorylation sites on spindle proteins 
upon Plk1 inactivation. 
Gene Names  Position  Local. Prob.  Spotting result  Modified Sequence 
ASPM  1825  1 positive  _QQS(ph)IAALK_ 
ASPM  480  0.507887 negative  _FSAVQDISS(ph)HSHNK_ 
ASPM  277  0.526316 NC  _AVT(ph)ETSFNSVNVNGQR_ 
ASPM  283  0.648605 negative  _AVTETSFNS(ph)VNVNGQR_ 
ASPM  479  0.844812 negative  _FSAVQDIS(ph)SHSHNK_ 
ASPM  355  0.854537 positive  _DNSQPVHLES(ph)TIAHEIYQK_ 
ASPM  356  0.889526 positive  _DNSQPVHLEST(ph)IAHEIYQK_ 
ASPM  279  0.975622 negative  _AVTET(ph)SFNSVNVNGQR_ 
ASPM  263  0.99979 negative  _ELLNVHS(ph)ANVSK_ 
ASPM  267  0.999981 positive  _ELLNVHSANVS(ph)K_ 
ASPM  280  0.999992 positive  _AVTETS(ph)FNSVNVNGQR_ 
ASPM  463  0.999995 negative  _SNYYS(ph)FIK_ 
ASPM  270  1 positive  _VS(ph)FNEK_ 
ASPM  3426  0.314908 positive  _NS(ph)SISIPFIPETPVR_ 
ASPM  3443  0.985525 negative  _TRIVS(ph)R_ 
ASPM  3425  0.990031 negative  _NS(ph)SISIPFIPETPVR_ 
ASPM  178  0.999243 positive  _T(ph)FSVSQK_ 
BLM  336  0.333333 negative  _EDVLS(ph)TSKDLLSKPEK_ 
BLM  337  0.483386 negative  _KEDVLST(ph)SK_ 
BLM  338  0.483386 negative  _KEDVLST(ph)SK_ 
BLM  1083  0.954642 negative  _DVTDDVKS(ph)IVR_ 
CDCA8  154  0.974926 NC  _TQS(ph)IQGK_ 
CDCA8  152  0.980595 negative  _RT(ph)QSIQGK_ 
CDCA8  169  0.999799 negative  _ANT(ph)VTPAVGR_ 
CDCA8  180  0.999981 positive  _LEVS(ph)M(ox)VKPTPGLTPR_ 
CDCA8  171  0.999983 negative  _ANTVT(ph)PAVGR_ 
CDCA8  106  1 negative  _LTAEAIQT(ph)PLK_ 
CDK5RAP2  1100  0.495431 negative  _VSVM(ox)GTDQS(ph)ESINTSNETEYLK_ 
CDK5RAP2  1102  0.495431 positive  _VSVM(ox)GTDQS(ph)ESINTSNETEYLK_ 
CDK5RAP2  1244  0.888278 negative  _DLSPPRYDS(ph)LVQSQAR_ 
CDK5RAP2  255  0.94 negative  _SQM(ox)ACPDENVS(ph)SGELR_ 
CDK5RAP2  706  0.999999 negative  _LASTEQTELLAS(ph)K_ 
CDK5RAP2  613  1 positive  _TLEEQIS(ph)EIR_ 
Q9H930 
(Uniprot)  180  1 negative  _QGEVPES(ph)PEAR_ 
NEDD1  332  0.971055 negative  _S(ph)VNVNAASGGVQNSGIVR_ 
NEDD1  384  0.999997 negative  _S(ph)INTDTLSK_ 
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NEDD1  339  0.999999 negative  _SVNVNAAS(ph)GGVQNSGIVR_ 
NEDD1  581  1 negative  _IADS(ph)IGNNR_ 
DLG7  827  0.483843 NC  _AGLEVLGSSDPTT(ph)SASR_ 
DLG7  828  0.989155 negative  _AGLEVLGSSDPTTS(ph)ASR_ 
DLG7  787  0.999611 negative  _IS(ph)QSELFDNK_ 
DLG7  774  0.999903 negative  _NTAS(ph)QNSILEEGETK_ 
DLG7  777  1 positive  _NTASQNS(ph)ILEEGETK_ 
CDC27  440  0.499972 NC  _LDS(ph)SIISEGK_ 
CDC27  444  0.824847 NC  _LDSSIIS(ph)EGK_ 
CDC27  441  0.996426 positive  _LDSS(ph)IISEGK_ 
CDCA7L  117  0.999896 negative  _ASLVS(ph)EEEEDEEEDKATPR_ 
CDCA7L  114  1 negative  _AS(ph)LVS(ph)EEEEDEEEDK_ 
CENPC1  104  0.478864 positive  _EAS(ph)LQFVVEPSEATNR_ 
CENPC1  515  0.857115 NC  _LVPEEVTS(ph)TVTK_ 
CENPC1  732  0.922007 negative  _LVLPS(ph)NTPNVR_ 
CENPC1  516  0.997091 positive  _LVPEEVTST(ph)VTK_ 
CENPC1  518  0.999636 NC  _LVPEEVTSTVT(ph)K_ 
CENPC1  734  0.999998 positive  _LVLPSNT(ph)PNVR_ 
CENPC1  439  1 negative  _PAEEQLDVGQS(ph)K_ 
CENPC1  96  1 positive  _EAS(ph)LQFVVEPSEATNR_ 
CENPC1  250  1 positive  _IRDS(ph)EYEIQR_ 
CENPC1  110  1 positive  _S(ph)VQAHEVHQK_ 
CENPC1  316  1 negative  _S(ph)WITIPR_ 
CENPF  1774  0.443244 negative  _NESCDISKEHT(ph)SETTER_ 
CENPF  1639  0.5 NC  _KET(ph)PSAPAK_ 
CENPF  3177  0.729498 negative  _SPT(ph)DSPREGLR_ 
CENPF  3175  0.829851 negative  _SVPVNNLPERS(ph)PTDSPR_ 
CENPF  1777  0.853823 negative  _EHTSET(ph)TERTPK_ 
CENPF  2512  0.895738 positive  _ISELEIINS(ph)SFENILQEK_ 
CENPF  1248  0.923143 positive  _GDLETS(ph)NLQDM(ox)QSQEISGLK_ 
CENPF  1748  0.928854 negative  _LQLQGLDLSS(ph)R_ 
CENPF  838  0.948684 positive  _VDSLEFS(ph)LESQK_ 
CENPF  1766  0.971172 negative  _NES(ph)CDISK_ 
CENPF  242  0.97434 positive  _DFS(ph)ASYFSGEQEVTPSR_ 
CENPF  1637  0.981015 negative  _KET(ph)PSAPAK_ 
CENPF  1747  0.996815 NC  _LQLQGLDLS(ph)SR_ 
CENPF  773  0.998991 negative  _SKDAS(ph)LVTNEDHQR_ 
CENPF  2513  0.999571 positive  _ISELEIINSS(ph)FENILQEK_ 
CENPF  876  0.999995 negative  _AEQM(ox)HQS(ph)FVAETSQR_ 
CENPF  1750  1 positive  _S(ph)LLGIDTEDAIQGR_ 
CENPF  1324  1 positive  _YELVTELNDS(ph)R_ 
CENPF  1988  1 positive  _VNDS(ph)WKER_ 
CENPI  709  0.5 positive  _TVNVS(ph)SIR_ 
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CENPI  710  0.5 NC  _TVNVS(ph)SIR_ 
CENPI  705  1 negative  _T(ph)VNVSSIR_ 
CENPJ  892  1 negative  _LNIS(ph)QDQPPGDNAR_ 
CENPL  53  1 positive  _KIPQCS(ph)QLQEDVDPQK_ 
CENPT  397  0.999776 negative  _AAS(ph)PESASSTPESLQAR_ 
CENPT  45  0.932011 positive  _RALLET(ph)ASPR_ 
CENPT  10  0.997079 negative  _(ac)ADHNPDSDS(ph)TPR_ 
CENPT  47  0.999999 negative  _ALLETAS(ph)PR_ 
MLF1IP  194  0.999999 positive  _TGPLSAQPS(ph)VEK_ 
CENPE  612  0.482225 positive  _M(ox)DLS(ph)YSLESIEDPK_ 
CENPE  611  0.914385 positive  _M(ox)DLS(ph)YSLESIEDPK_ 
CEP192  1484  1 negative  _AS(ph)LESTSDLGASGK_ 
CEP192  1502  1 positive  _HGGNVS(ph)LDVLPVK_ 
CEP192  285  0.838187 negative  _T(ph)CSIDNKLQDVGNDEK_ 
CEP192  287  0.984293 negative  _TCS(ph)IDNKLQDVGNDEK_ 
CEP72  387  0.928274 negative  _TLSQPEAS(ph)ETEEQR_ 
CEP97  308  0.967084 positive  _QLM(ox)NQS(ph)QNEELSPLVPVETR_ 
CEP350  2689  0.999107 positive  _VSIAAEDDTLDNT(ph)FSEELEK_ 
KIF4A  953  0.5 NC  _QLEES(ph)VSEK_ 
KIF4A  951  0.999675 negative  _QLEES(ph)VSEK_ 
KIF4A  810  0.99974 negative  _GQVS(ph)ESEDSITK_ 
KIF4A  815  0.999801 positive  _GQVSESEDS(ph)ITK_ 
KIF4B  1038  1 negative  _FLEQS(ph)MDIEDLK_ 
KIF4B  394  1 positive  _NQS(ph)LVEENEK_ 
CCDC86  110  0.886644 negative  _QPEYS(ph)PESPR_ 
CCDC86  113  0.989544 negative  _QPEYSPES(ph)PR_ 
CCDC86  58  1 negative  _AGLGS(ph)PERPPK_ 
NCAPH  16  0.451243 negative  _M(ox)GPPGPALPATM(ox)NNS(ph)SSETR_ 
NCAPH  98  0.886582 positive  _SIDISAT(ph)IPK_ 
NCAPH  17  0.903612 negative  _GPPGPALPATM(ox)NNSSS(ph)ETR_ 
NCAPH  96  0.939989 negative  _SIDIS(ph)ATIPK_ 
NCAPH  201  0.954973 negative  _DAPSLEEVEGHVADGS(ph)ATEM(ox)GTTK_ 
NCAPH  203  0.976778 negative  _DAPSLEEVEGHVADGSAT(ph)EMGTTK_ 
NCAPH  15  0.993995 NC  _GPPGPALPATM(ox)NNS(ph)SSETR_ 
NCAPH  92  0.995883 negative  _S(ph)IDISATIPK_ 
NCAPH  233  1 negative  _TIEQNINNLNVS(ph)EADR_ 
NCAPG  390  0.999999 negative  _GDFS(ph)YIGNLMTK_ 
NCAPD3  430  0.920321 positive  _EVDNT(ph)LSLEHQK_ 
NCAPD3  325  0.974873 negative  _APLAVTS(ph)QVINCR_ 
NCAPD3  508  0.99979 positive  _NSS(ph)AFSYQR_ 
NCAPD3  1250  0.999997 negative  _QLAS(ph)ELEYDM(ox)K_ 
NCAPG2  1114  0.993942 positive  _T(ph)FM(ox)EITLEEDSIER_ 
NCAPG2  1119  0.999923 negative  _TFM(ox)EIT(ph)LEEDSIER_ 
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NCAPG2  30  0.999969 positive  _EAS(ph)DPFSLNELLDELSR_ 
NCAPG2  605  1 NC  _ENVT(ph)VLDK_ 
DYNC1LI1  516  0.871028 negative  _KPVTVSPTTPTS(ph)PTEGEAS_ 
CKAP2  533  0.99993 positive  _EVS(ph)IEDTGVDVDPEK_ 
DOCK7  907  0.460531 negative  _SLSNSNPDISGT(ph)PTSPDDEVR_ 
DOCK7  909  0.460531 negative  _SLSNSNPDISGT(ph)PTSPDDEVR_ 
TOP2A  282  0.5 positive  _DKLDET(ph)GNSLK_ 
TOP2A  285  0.5 negative  _DKLDET(ph)GNSLK_ 
TOP2A  1458  1 NC  _SVVS(ph)DLEADDVK_ 
RANBP2  2280  0.995942 NC  _SALSPSKS(ph)PAK_ 
RANBP2  2293  0.996196 negative  _LNQSGTSVGT(ph)DEESDVTQEEER_ 
RANBP2  2450  0.999573 NC  _DSLIT(ph)PHVSR_ 
RANBP2  2454  0.999936 negative  _DSLITPHVS(ph)R_ 
TOPORS  98  0.999991 negative  _LQQTVPADAS(ph)PDSK_ 
EML3  208  1 negative  _S(ph)NYNLEGISVK_ 
EPPK1  2508  1 negative  _AEAEAGS(ph)PRPDPR_ 
ERCC6L  805  0.499844 negative  _GT(ph)GSADSIATLPK_ 
ERCC6L  790  0.5 positive  _QDLS(ph)SIK_ 
ERCC6L  791  0.934394 NC  _QDLSS(ph)IK_ 
ERCC6L  807  0.998481 negative  _GTGS(ph)ADSIATLPK_ 
ERCC6L  14  1 negative  _FPEAEALS(ph)PEQAAHYLR_ 
ERCC6L  774  1 positive  _M(ox)AS(ph)VVIDDLPK_ 
ERCC6L  995  1 negative  _AGFVHS(ph)K_ 
FANCD2  592  0.991802 negative  _SES(ph)PSLTQER_ 
FNBP4  432  0.997156 negative  _ALEEGDGSVSGSS(ph)PR_ 
TUBGCP2  873  1 negative  _LERLS(ph)AER_ 
TUBGCP2  899  0.886792 negative  _LRVSLGT(ph)R_ 
TUBGCP2  896  0.999999 negative  _VS(ph)LGTR_ 
TUBGCP5  182  1 positive  _EDS(ph)GIQVDR_ 
TUBGCP6  1068  0.999993 NC  _VGENVS(ph)DVAPTQPR_ 
TUBGCP6  1230  1 negative  _VGENVS(ph)DVAPIR_ 
HSPB1  199  0.997277 negative  _AQLGGPEAAKS(ph)DETAAK_ 
HSPB1  65  1 negative  _PLPPAAIES(ph)PAVAAPAYSR_ 
HSPB1  15  1 negative  _GPS(ph)WDPFR_ 
HMMR  65  1 NC  _DTTLPAS(ph)AR_ 
HMMR  704  1 negative  _ENFALKT(ph)PLK_ 
KPNA2  490  0.999998 negative  _ASLS(ph)LIEK_ 
INCENP  509  0.49832 negative  _NQM(ox)LM(ox)TPT(ph)SAPR_ 
INCENP  420  0.769604 negative  _PAAS(ph)SPETPSAGQQEAK_ 
INCENP  915  0.848169 negative  _VPSS(ph)LAYSLKKH_ 
INCENP  294  0.908119 negative  _VLAPILPDNFSTPT(ph)GSR_ 
INCENP  510  0.924064 negative  _NQM(ox)LM(ox)TPTS(ph)APR_ 
INCENP  94  0.972951 negative  _SS(ph)QLSSR_ 
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INCENP  93  0.985121 negative  _S(ph)SQLSSR_ 
INCENP  914  0.98594 negative  _VPS(ph)SLAYSLK_ 
INCENP  507  0.995107 negative  _NQMLMT(ph)PTSAPR_ 
INCENP  323  0.999999 NC  _YS(ph)LVAK_ 
INCENP  72  1 positive  _RIS(ph)YVQDENR_ 
INCENP  524  1 negative  _RNT(ph)PLRM(ox)DPK_ 
INCENP  350  1 negative  _TAEEPAAS(ph)GR_ 
INCENP  330  1 positive  _QES(ph)VVR_ 
KIF11  931  0.999928 NC  _S(ph)YLYPSTLVR_ 
KIF18A  695  0.995156 negative  _SPPSQSVQLNDS(ph)LSK_ 
KIF20A  48  0.46704 negative  _NLLSDCSVVST(ph)SLEDK_ 
KIF20A  558  0.5 positive  _ADTGLDDDIENEADIS(ph)M(ox)YGK_ 
KIF20A  47  0.811131 negative  _NLLSDCSVVS(ph)TSLEDK_ 
KIF20A  635  0.853842 positive  _ESLTS(ph)FYQEEIQER_ 
KIF20A  662  0.957139 negative  _QQS(ph)VAHQQSGSELALR_ 
KIF20A  670  0.963194 negative  _QQSVAHQQSGS(ph)ELALR_ 
KIF20A  668  0.964931 negative  _QQSVAHQQS(ph)GSELALR_ 
KIF20A  49  0.999532 negative  _NLLSDCSVVSTS(ph)LEDK_ 
KIF20A  41  0.999761 negative  _NLLS(ph)DCS(ph)VVSTSLEDK_ 
KIF20A  44  0.999924 negative  _NLLSDCS(ph)VVS(ph)TSLEDK_ 
KIF20A  244  1 negative  _S(ph)VYIESR_ 
KIF20A  825  1 NC  _LQGQVS(ph)AKK_ 
KIF20A  556  1 negative  _ADTGLDDDIENEADIS(ph)MYGK_ 
KIF20A  109  1 negative  _DSFALKS(ph)NER_ 
KIFC1  33  0.499915 positive  _APSQLPLS(ph)GSR_ 
KIFC1  31  0.99985 NC  _APSQLPLS(ph)GSR_ 
NDC80  49  0.916435 NC  _LSINKPT(ph)SER_ 
NDC80  50  0.996448 negative  _LSINKPTS(ph)ER_ 
NDC80  44  0.998157 NC  _LS(ph)INKPTSER_ 
NDC80  55  1 NC  _KVS(ph)LFGK_ 
DSN1  38  0.423053 negative  _T(ph)SASLEM(ox)NQGVSEER_ 
DSN1  39  0.425809 negative  _TS(ph)ASLEMNQGVSEER_ 
DSN1  41  0.90672 negative  _TSAS(ph)LEM(ox)NQGVSEER_ 
DSN1  125  0.999799 negative  _SIS(ph)VDLAESK_ 
DSN1  123  0.999999 negative  _S(ph)ISVDLAESK_ 
DSN1  331  1 negative  _SMQQLDPS(ph)PAR_ 
NSL1  22  0.493728 negative  _ELAAGT(ph)ESQALVSATPR_ 
NSL1  24  0.902749 negative  _ELAAGTES(ph)QALVSATPR_ 
CENPB  306  0.5 positive  _LAAQSLDT(ph)SGLR_ 
CENPB  307  0.995467 positive  _LAAQSLDTS(ph)GLR_ 
MAP7D1  113  0.302259 NC  _RSS(ph)QPSPTAVPASDSPPTKQEVK_ 
MAP7D1  118  0.302259 negative  _RSS(ph)QPSPTAVPASDSPPTKQEVK_ 
MAP7D1  123  0.302259 negative  _RSS(ph)QPSPTAVPASDSPPTKQEVK_ 
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MAP7D1  316  0.95963 NC  _SRSAVT(ph)LPR_ 
MAP7D1  452  0.999976 negative  _ARLS(ph)ASTASELSPK_ 
BUB1  306  0.5 negative  _LHQVVET(ph)SHEDLPASQER_ 
BUB1  314  0.634657 negative  _LHQVVETSHEDLPAS(ph)QERSEVNPAR_ 
BUB1  307  0.812046 negative  _KLHQVVETS(ph)HEDLPASQER_ 
BUB1  661  1 positive  _FS(ph)PIQEKS(ph)PK_ 
MYBBP1A  1163  0.999989 NC  _EIPSATQS(ph)PISK_ 
Em:U62317.2  493  1 negative  _FVQETELS(ph)QR_ 
Em:U62317.2  96  0.997212 negative  _QLSS(ph)VQEDR_ 
NUMA1  1788  0.903678 negative  _SQAPLES(ph)SLDSLGDVFLDSGR_ 
NUMA1  1818  0.905349 positive  _TTQIINIT(ph)M(ox)TK_ 
NUP107  45  0.883423 negative  _VLLQASQDENFGNT(ph)TPR_ 
NUP107  57  0.8837 positive  _TPS(ph)SFRQPFTPTSR_ 
NUP107  4  1 positive  _S(ph)GFGEISSPVIR_ 
NUP153  520  0.383793 negative  _VQM(ox)TSPS(ph)STGSPM(ox)FK_ 
NUP153  518  0.418952 negative  _VQM(ox)TS(ph)PSSTGSPM(ox)FK_ 
NUP153  515  0.829829 negative  _VQM(ox)T(ph)SPSSTGSPM(ox)FK_ 
NUP153  522  0.978026 NC  _VQM(ox)TSPSSTGS(ph)PM(ox)FK_ 
NUP153  516  0.988075 negative  _VQM(ox)TS(ph)PSSTGSPM(ox)FK_ 
NUP153  343  1 positive  _S(ph)GIDITDFQAK_ 
NUP88  540  1 positive  _S(ph)VANPAFLK_ 
NUP93  75  0.999965 negative  _GLDISHIS(ph)QR_ 
NUP93  72  1 positive  _GLDIS(ph)HIS(ph)QR_ 
NUP98  980  0.893409 negative  _AS(ph)LLTDEEDVDM(ox)ALDQR_ 
NUP98  983  0.970659 negative  _ASLLT(ph)DEEDVDM(ox)ALDQR_ 
NUP98  591  0.998516 positive  _NLNNS(ph)NLFSPVNR_ 
NUP98  606  0.999997 negative  _DSENLAS(ph)PSEYPENGER_ 
NUP98  595  1 negative  _NLNNSNLFS(ph)PVNR_ 
NPM1  198  1 positive  _KGQES(ph)FK_ 
NUP188  1709  0.991639 negative  _GAPSS(ph)PATGVLPSPQGK_ 
NUP188  1523  0.999703 negative  _VQRPPS(ph)AASAAPSSSK_ 
NUP43  361  0.743713 negative  _SS(ph)LFHQGGR_ 
NUP35  73  1 negative  _SPLLAGGS(ph)PPQPVVPAHK_ 
TPR  1185  0.99272 positive  _EGVQGPLNVS(ph)LSEEGK_ 
PCNT  1690  0.499995 positive  _LDMQNS(ph)QTAVSLR_ 
PCNT  3325  0.817391 positive  _LGGVLPDST(ph)SK_ 
PCNT  2479  0.926108 negative  _LSGS(ph)DLGGHSSLLER_ 
PCNT  815  0.975834 positive  _SLT(ph)EQQGR_ 
PCNT  813  0.982922 positive  _S(ph)LTEQQGR_ 
PCNT  1688  0.998154 positive  _LDM(ox)QNS(ph)QTAVSLR_ 
PCNT  2594  0.999999 positive  _TLSEEQEKANS(ph)VQK_ 
PCNT  1653  1 negative  _RES(ph)EVLDLKEQLEK_ 
PCNT  2963  1 negative  _RAAGS(ph)DADHLREQQR_ 
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PCNT  2044  1 negative  _NEMRLS(ph)LEDGGK_ 
PCNT  2860  1 negative  _ELRCS(ph)LER_ 
PCNT  2433  1 negative  _KEDEIQDIS(ph)LHGGK_ 
PCNT  682  1 negative  _VQLS(ph)LLQTELK_ 
PCNT  201  0.998933 negative  _GIFTIS(ph)DHPAEQR_ 
PCM1  861  0.999321 negative  _QGLAETAS(ph)PVAVSLR_ 
PCM1  110  1 positive  _INFS(ph)DLDQR_ 
PLEC1  4389  0.90212 negative  _SSSVGS(ph)SSSYPISPAVSR_ 
CASC5  1805  0.465659 negative  _S(ph)ANSVLIKNLSR_ 
CASC5  479  0.909009 negative  _TIYS(ph)GEENM(ox)DITK_ 
CASC5  1013  0.978665 positive  _LVANDS(ph)QLTPLEEWSNNR_ 
CASC5  1808  0.999998 positive  _SANS(ph)VLIK_ 
FAM83B  334  0.969072 negative  _LDS(ph)SYFK_ 
FAM83D  368  0.863728 NC  _LARLS(ph)STPR_ 
PRC1  593  0.479591 negative  _DPSLSDSS(ph)TVGLQR_ 
PRC1  592  0.935751 positive  _DPSLSDSS(ph)TVGLQR_ 
DKFZp434J046  1147  0.451398 negative  _AGTGY(ph)ASPDRTHVLAAGK_ 
DKFZp434J046  1145  0.60411 negative  _AGT(ph)GYASPDRTHVLAAGK_ 
DKFZp434J046  975  0.901806 negative  _KEVEAGPGDQQGDSY(ph)LR_ 
DKFZp434J046  1149  0.999998 negative  _AGTGYAS(ph)PDR_ 
DKFZp434J046  974  1 positive  _KEVEAGPGDQQGDS(ph)YLR_ 
Q86Y91 
(Uniprot)  443  1 negative  _ALQEES(ph)LGM(ox)EAQVER_ 
RACGAP1  169  0.5 NC  _TDESLDWDS(ph)SLVK_ 
RACGAP1  164  0.999731 positive  _TDES(ph)LDWDSSLVK_ 
RACGAP1  170  0.999836 positive  _TDESLDWDSS(ph)LVK_ 
RACGAP1  214  1 positive  _SIGSAVDQGNES(ph)IVAK_ 
RGPD8  1534  1 NC  _AVVS(ph)PPK_ 
RGPD8  21  0.999697 negative  _YVASVLGLTPS(ph)PR_ 
ARHGEF2  737  0.722985 positive  _S(ph)ESLESPRGER_ 
ARHGEF2  739  0.998405 negative  _SES(ph)LESPR_ 
SENP3  57  0.821678 NC  _SGGGFGPDPGSGTT(ph)VPAR_ 
AURKB  61  0.93013 negative  _VM(ox)ENS(ph)SGTPDILTR_ 
AURKB  62  0.994939 negative  _VM(ox)ENSS(ph)GTPDILTR_ 
AURKB  19  0.997002 negative  _QTAPS(ph)GLSTLPQR_ 
AURKB  16  0.997888 negative  _QT(ph)APSGLSTLPQR_ 
AURKB  35  0.999987 negative  _KEPVT(ph)PSALVLM(ox)SR_ 
AURKB  7  0.999999 negative  _(ac)AQKENS(ph)YPWPYGR_ 
AURKB  45  1 negative  _S(ph)NVQPTAAPGQK_ 
AURKB  236  0.333333 negative  _KT(ph)M(ox)CGTLDYLPPEM(ox)IEGR_ 
AURKB  239  0.333333 positive  _KT(ph)M(ox)CGTLDYLPPEM(ox)IEGR_ 
AURKB  232  0.999944 negative  _T(ph)M(ox)CGTLDYLPPEM(ox)IEGR_ 
MARK2  569  0.989246 negative  _VPVAS(ph)PSAHNISSSGGAPDR_ 
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PLK1  326  1 negative  _FS(ph)IAPSSLDPSNR_ 
PRPF4B  277  0.999999 NC  _KKS(ph)PIINESR_ 
SHCBP1  5  0.999369 negative  _(ac)ADGS(ph)LTGGGLEAAAM(ox)APER_ 
SGOL2  436  0.740113 positive  _TERS(ph)DVLDGKR_ 
SGOL2  1150  0.841756 NC  _SLSEIHSPNIQDS(ph)SFDSVR_ 
SGOL2  421  0.921569 negative  _NSS(ph)DVDIGEKIENR_ 
SGOL2  433  0.992403 negative  _T(ph)ERSDVLDGK_ 
PDS5B  1359  0.858497 negative  _AES(ph)PESSAIESTQSTPQK_ 
SON  97  0.838414 negative  _CVSVQT(ph)DPTDEIPTKK_ 
SON  2020  0.988273 NC  _S(ph)RTPLR_ 
SON  160  0.997173 NC  _FDS(ph)EPSAVALELPTR_ 
SON  94  0.999614 negative  _CVS(ph)VQTDPTDEIPTK_ 
SON  152  0.999878 NC  _SHDDGNIDLES(ph)DSFLK_ 
SON  2022  1 NC  _S(ph)RT(ph)PLRR_ 
SON  154  1 positive  _SHDDGNIDLESDS(ph)FLK_ 
SPAG5  400  0.393666 negative  _STNT(ph)SQTGLVGTK_ 
SPAG5  50  0.398686 negative  _SPACSSLT(ph)PSLCK_ 
SPAG5  114  0.651142 negative  _T(ph)SEEAVDPLGNYM(ox)VK_ 
SPAG5  115  0.74228 negative  _TS(ph)EEAVDPLGNYM(ox)VK_ 
SPAG5  403  0.930181 negative  _STNTSQT(ph)GLVGTK_ 
SPAG5  401  0.987596 positive  _STNTS(ph)QTGLVGTK_ 
SPAG5  159  0.997926 negative  _LDTM(ox)AETNSIS(ph)LNGPLR_ 
SPAG5  157  0.999591 negative  _LDTM(ox)AETNS(ph)ISLNGPLR_ 
SSFA2  737  0.579884 positive  _S(ph)QSLPTTLLS(ph)PVR_ 
SSFA2  1161  0.896832 negative  _ASVALTPTAPS(ph)R_ 
SSFA2  739  0.97224 positive  _SQS(ph)LPTTLLSPVR_ 
SSFA2  746  0.999919 negative  _SQS(ph)LPTTLLS(ph)PVR_ 
SSFA2  668  1 negative  _SLAS(ph)IEAK_ 
TPX2  358  0.652646 NC  _KDDINLLPSKS(ph)SVTK_ 
TPX2  361  0.695135 positive  _KDDINLLPSKSSVT(ph)K_ 
TPX2  359  0.794102 NC  _KDDINLLPSKSS(ph)VTK_ 
TPX2  356  0.934409 positive  _DDINLLPS(ph)KSSVTK_ 
TPX2  80  0.499997 negative  _KANLQQAIVT(ph)PLKPVDNTYYK_ 
TPX2  646  0.82756 negative  _S(ph)VAEGLSGSLVQEPFQLATEK_ 
TPX2  652  0.99448 negative  _SVAEGLS(ph)GSLVQEPFQLATEK_ 
TPX2  654  0.999767 positive  _SVAEGLSGS(ph)LVQEPFQLATEK_ 
TPX2  174  0.999781 negative  _KPEEEGS(ph)AHQDTAEK_ 
TPX2  72  1 negative  _ANLQQAIVT(ph)PLKPVDNTYYK_ 
TPX2  369  1 negative  _DPQT(ph)PVLQTK_ 
TPX2  486  1 negative  _S(ph)PAFALKNR_ 
TPX2  113  1 negative  _KT(ph)PAQPQR_ 
TUBA1C  51  0.407613 negative  _TIGGGDDS(ph)FNTFFSETGAGK_ 
TUBA1C  48  0.999533 positive  _TIGGGDDS(ph)FNTFFSETGAGK_ 
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TUBA1C  41  0.999999 positive  _T(ph)IGGGDDSFNTFFSETGAGK_ 
C14orf106  134  0.446311 NC  _DKQEQPSRNS(ph)SLLEPQK_ 
C14orf106  191  0.49996 negative  _ASVQGVPLES(ph)SNNDIFLPVK_ 
C14orf106  192  0.49996 positive  _ASVQGVPLES(ph)SNNDIFLPVK_ 
C14orf106  135  0.999675 positive  _NSS(ph)LLEPQK_ 
C13orf3  319  0.493847 negative  _TNSS(ph)SNDLEVEDR_ 
C13orf3  318  0.932538 negative  _TNSS(ph)SNDLEVEDR_ 
C13orf3  317  0.977196 negative  _TNS(ph)SSNDLEVEDR_ 
C18orf21  158  0.999805 NC  _GKS(ph)PASVFR_ 
CENPN  226  1 positive  _S(ph)LGLDINMDSR_ 
CENPN  282  1 positive  _SGLNGS(ph)ILAER_ 
CENPN  235  1 positive  _SLGLDINM(ox)DS(ph)R_ 
CIT  433  0.997708 negative  _SES(ph)VVSGLDSPAK_ 
ITGB3BP  112  0.495291 negative  _LNHPS(ph)LTESK_ 
ITGB3BP  110  0.999986 negative  _LNHPS(ph)LTESK_ 
KIF23  897  0.548666 positive  _GGGQSVQFTDIET(ph)LKQESPNGSR_ 
KIF23  889  0.999994 positive  _GGGQS(ph)VQFTDIETLK_ 
KIF23  450  1 NC  _AICGLT(ph)PGRR_ 
MAP7  200  0.997359 negative  _RLS(ph)SSSATLLNSPDR_ 
VIM  458  0.988223 positive  _DGQVINET(ph)SQHHDDLE_ 
VIM  459  0.993847 positive  _DGQVINETS(ph)QHHDDLE_ 
VIM  83  0.999979 positive  _LLQDS(ph)VDFSLADAINTEFK_ 
VIM  409  1 positive  _LLEGEES(ph)R_ 
VIM  299  1 negative  _FADLS(ph)EAANR_ 
 
NC= non-conclusive sites. Positive also in the membrane incubated with ATP alone or showing the 
same signal intensity in the A version of the peptide. 
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